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ABSTRACT 
ASSESSING MECHANISMS DRIVING INCREASED NICOTINE USE IN
 SCHIZOPHRENIA USING THE MAM RODENT MODEL 
Jillian J. Weeks, Ph.D. 
University of Pittsburgh, 2020 
Rates of smoking are 2-3 times higher among individuals with schizophrenia relative 
to the general population, posing a significant exacerbation of health and socioeconomic 
disparities. While the cause of this elevation is unknown, two prevalent hypotheses are that 
nicotine, the primary reinforcing component in cigarettes, is particularly rewarding to 
individuals with schizophrenia, or that these smokers smoke in an attempt to “self-medicate” 
their symptoms. The present study utilized the methylazoxymethanol (MAM) 
neurodevelopmental rodent model of schizophrenia to evaluate these hypotheses. In order to 
explore the “reinforcement hypothesis”, MAM and control (CTL) animals were allowed to self-
administer nicotine across a range of doses and responding and intake of nicotine were 
compared. The “self-medication” hypothesis was evaluated by examining the effects of acute 
and chronic nicotine on several established behavioral paradigms known to be disrupted in the 
MAM model. Additionally, the effects of acute and chronic nicotine on neurophysiological 
dysfunction, including elevated VTA dopamine population activity and elevated ventral 
hippocampal (vHipp) activity, were observed. Our findings demonstrated that self-administration 
of nicotine, alone or in combination with another reinforcer, was not increased in MAM rats, 
suggesting that schizophrenia pathophysiology modeled by MAM does not confer increased 
nicotine reinforcement. Conversely, we observed nicotine-induced improvements in prepulse 
inhibition of startle and novel object recognition among MAM rats, as well as a
v 
normalization of elevated VTA dopamine and vHipp neuronal activity in these animals. 
Together, these findings lend greater support for a “self-medication” hypothesis behind 
increased smoking in schizophrenia and illustrate the potential utility of nicotinic 
modulation in future pharmacotherapies for certain schizophrenia symptoms. 
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PREFACE 
The work presented in Chapter 2 is based on a previously published manuscript: 
Weeks JJ, Rupprecht LE, Grace AA, Donny EC, & Sved AF. Nicotine Self-administration is Not 
Increased in the Methylazoxymethanol Acetate Rodent Model of Schizophrenia, Nicotine & 
Tobacco Research, 2020, Volume 22, Issue 2, Pages 204-212, by permission of the Society 
for Research on Nicotine & Tobacco. 
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1.0 INTRODUCTION 
1.1 CIGARETTE SMOKING IN SCHIZOPHRENIA: AN OVERVIEW 
Cigarette smoking remains the largest preventable cause of death in the United States, 
contributing to multiple serious diseases and impacting overall health of smokers (U.S. 
Department of Health and Human Services 2014). Overall smoking rates have decreased steadily 
over time as public awareness of these health risks has grown. Currently, an estimated 13-15% of 
U.S. adults are smokers, though this figure encompasses a tobacco use and disease burden 
disproportionately affecting vulnerable populations (Drope et al. 2018). In particular, higher 
smoking rates are reported among those with serious mental illnesses (SMI), with the highest 
prevalence among schizophrenia (SCZ) patients. SCZ is a chronic and severe mental disorder that 
affects roughly 1% of the population. It disrupts an individual’s ability to process and perceive 
reality clearly and is characterized by a variety of symptoms, including delusions, auditory and 
visual hallucinations, disorganized speech and behavior, anhedonia, and cognitive impairments 
(McCutcheon et al. 2019).  A study by Dickerson and colleagues (Dickerson et al. 2018) spanning 
1999-2016 found that, overall, 62% of SCZ patients were smokers, compared with 37% of those 
with bipolar disorder and 17% of controls. Moreover, roughly half of all deaths in individuals with 
SMI are attributed to tobacco-related illness, making smoking cessation in this population an 
urgent priority (Callaghan et al. 2014). 
In addition to being more likely to smoke overall, individuals with SCZ display a distinctly 
heavy pattern of smoking (de Leon and Diaz 2005). Smokers with SCZ smoke more cigarettes per 
day than controls, are more likely to be nicotine (NIC) dependent, and tend to smoke more 
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intensely (Dickerson et al. 2018; Stewart et al. 2013). A study of smoking topography found that 
smokers with SCZ take more puffs per cigarette, with larger puff volumes, shorter inter-puff 
intervals, and greater levels of expired carbon monoxide than controls without SMI (Tidey et al. 
2005). This intense pattern of smoking contributes to high rates of smoking-related illness, 
exacerbating the massive health disparity faced by this population. For example, smokers with 
SCZ are significantly more likely than controls to be diagnosed with respiratory diseases, tobacco-
related cancers, and cardiovascular diseases (Krieger et al. 2019; Tran et al. 2009) Individuals with 
SCZ face an overall estimated reduction in life expectancy of 13-15 years relative to the general 
population (Hjorthøj et al. 2017). Smoking furthers this discrepancy within the patient population. 
An 11-year prospective study of SCZ patients by Dickerson and colleagues (Dickerson et al. 2014) 
found that those who smoked were 5 times more likely to die of “natural causes” (largely 
encompassing cardiovascular ailments) than nonsmoking patients. Despite these clear health 
consequences, success in smoking cessation in this population has been limited by a number of 
factors. Smokers with SCZ are more likely to experience greater barriers to cessation, including 
higher levels of dependence, prosmoking social norms, financial stress, unemployment, and a lack 
of access to cessation support or nicotine replacement therapies (Lum et al. 2018). Unfortunately, 
this discrepancy is also perpetuated in both inpatient and outpatient treatment. Tobacco use is often 
a low priority issue in primary care settings for SCZ patients due to the complex competing 
demands of their condition (Cerimele et al. 2014). Additionally, psychiatrists, who are main 
consistent healthcare contact for many patients, are less likely than other providers to encourage 
smoking cessation (Hall and Prochaska 2009). This is despite the fact that smokers with SCZ 
generally report a high level of motivation to quit, even among patients with greatest symptom 
severity (Anzai et al. 2015). In inpatient psychiatric care settings, smoking bans remain a 
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contentious issue in ethics and patient autonomy, since many patients cannot leave (Woodward 
and Richmond 2019). Smoking places a major financial burden on SCZ patients as well, many of 
whom live on fixed, limited incomes. A study of SCZ smokers on public assistance found that an 
average 30% of their monthly income was spent on cigarettes, severely limiting access to other 
resources that may improve quality of life (Steinberg et al. 2004). There is a growing awareness 
of the urgent need for smoking cessation among patients with SCZ, but the unique barriers faced 
by this population require distinct approaches to reaching this goal. 
1.2 A REINFORCEMENT-BASED HYPOTHESIS OF INCREASED SMOKING IN 
SCHIZOPHRENIA 
While the high rate of smoking among individuals with SCZ is well-documented, the 
underlying etiology remains unclear. This discrepancy cannot be attributed purely to 
environmental and psychosocial factors, as it persists even when controlling for factors such as 
socioeconomic status, institutionalization, employment, and education level (Hughes et al. 1986). 
A commonly suggested hypothesis is that SCZ confers neurobiological, reward-related risk factors 
that contribute to tobacco use beyond the psychosocial factors that limit cessation. Indeed, rates of 
co-occurring substance use disorders (SUDs) are high among those with SCZ, with overall 
reported SUDs occurring at more than twice the rate of those in the general population. Addiction 
to nicotine (NIC), the primary psychoactive and reinforcing component of tobacco, is widely 
accepted as the main driver of tobacco smoking and represents the most prevalent SUD among 
patients (Volkow 2009). A common proposal suggests that the hippocampal-prefrontal 
dysregulation of dopamine (DA) release in the nucleus accumbens (NAcc) observed in SCZ may 
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contribute to positive symptoms of the disease as well as a heightened addiction vulnerability 
(Chambers et al. 2001). This vulnerability is largely associated with an impaired sensitivity to 
reward observed in SCZ patients. Anhedonia, a reduction in capacity for pleasant and rewarding 
emotion, is a hallmark symptom of SCZ that is often resistant to treatment (Horan et al. 2006). 
Anhedonia in this population largely manifests as a reduction in anticipatory pleasure; studies 
suggest that SCZ patients do not differ from controls in self-reports of current pleasant mood, but 
tend to underestimate expected pleasure from future events and experienced pleasure from past 
events (Strauss 2013). This suggests that anhedonia in this population is more related to how 
patients conceptualize, anticipate, and learn about reward, rather than how reward is experienced 
in the present.  
Many studies suggest that reward-related dysfunction is related to increased smoking 
among SCZ patients. In a 2012 study by AhnAllen and colleagues (2012), SCZ and control 
smokers were administered a signal detection task to assess reward-based learning. While SCZ 
smokers did not differ from controls in overall patterns of reward-based learning, decreased 
performance was associated with increased NIC dependence and increased anhedonia specifically 
among patients. This suggests that reward dysfunction may drive NIC intake, particularly in those 
patients with the highest levels of dependence. The unique reinforcing effects of NIC may explain 
why the use of tobacco is so prevalent. Like other drugs of abuse, NIC directly stimulates phasic 
DA release in striatum, which is associated with its rewarding effects (Rice and Cragg 2004). A 
wealth of both clinical and preclinical data have established that, in addition to its primary 
reinforcing effects, NIC increases responsivity to non-drug rewards, an effect known as 
reinforcement enhancement (Perkins et al. 2017; Rupprecht et al. 2015). Thus, NIC may mitigate 
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an underlying reduction in hedonic capacity and reward-based learning in smokers with SCZ by 
increasing responsivity to reward in general.  
In addition to studying the effect of smoking on reward-based learning, clinical studies 
related to this phenomenon have focused on comparing the rewarding effects of smoking relative 
to other rewards in SCZ smokers versus control smokers. A study by Spring and colleagues (2003) 
sought to assess perceived smoking reward in heavy smokers with SCZ, depression (a disorder 
also characterized by anhedonia), and nonpsychiatric controls. Subjects were asked to rate their 
perception of relative benefits versus drawbacks of smoking to create a pro/con “balance sheet” 
while controlling for dependence as measured by Fagerstrom Test for Nicotine Dependence 
(FTND). Despite acknowledging risks and drawbacks of smoking, both groups of patients were 
more likely to rate the overall effects of smoking as positive, while nonpsychiatric controls tended 
to find nearly equal pros and cons. Subjects also completed a forced-choice task where they made 
hypothetical selections between smoking and alternative rewards such as receiving a gift or eating 
a favorite candy. Psychiatric subjects were twice as likely than controls to select smoking over 
alternative rewards, and smokers with SCZ did not differ from those with depression (Spring et al. 
2003). These results suggest that heavy smokers with depression or SCZ, conditions marked by 
reward processing dysfunction, may find smoking more rewarding than controls.  
More targeted assessments of motivation to smoke provide greater insight into the 
reinforcement hypothesis as well. A behavioral economic assessment of smokers with SCZ by 
MacKillop & Tidey (2011) aimed to characterize cigarette demand and delayed reward 
discounting, a behavioral economic measure of impulsivity. In prior studies of delayed reward 
discounting, individuals with SCZ tended to discount delayed monetary rewards more steeply than 
nonpsychiatric controls regardless of smoking status, suggesting a higher level of impulsivity and 
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a preference for immediate over long-term rewards (Heerey et al. 2007). This preference is 
consistent with established impairments in evaluation of future or past rewarding experiences in 
SCZ (Strauss 2013). Interestingly, MacKillop and Tidey (2011) found that SCZ smokers 
demonstrated less impulsive delay discounting than control smokers, suggesting that impulsive 
reward preferences may not be a variable motivating particularly high smoking in this population. 
Subjects’ demand for cigarettes was also assessed using a hypothetical cigarette purchase task 
(CPT), where subjects were asked to report how many cigarettes they would smoke at a given 
price if they were available currently (i.e. they could not be stockpiled and smoked at a later time). 
Smokers with SCZ demonstrated significantly greater intensity of demand than control smokers. 
While they were sensitive to changes in price, SCZ subjects reported higher levels of expenditure 
(i.e. greater hypothetical consumption of cigarettes) in the CPT at the five lowest price points. In 
general, this finding is consistent with established evidence that smokers with SCZ smoke more 
cigarettes per day and spend a greater proportion of their income on cigarettes than control 
smokers, and does suggest differences in the valuation of cigarettes between these populations 
(Dickerson et al. 2018; Steinberg et al. 2004).  
Behavioral demonstration of the reinforcing value of cigarettes as a piece of evidence for 
a “reinforcement hypothesis” behind increased smoking is challenging. A second popular theory 
explaining high rates of tobacco use in SCZ is the “self-medication hypothesis”, which suggests 
that smoking serves as a means of normalizing or alleviating underlying pathology of the disease 
(Leonard et al. 2007). It is difficult to fully disentangle a greater subjective rating of smoking in 
SCZ patients from a broadly defined self-medication hypothesis, as self-medication could 
encompass feeling “better”, which is reinforcing in itself, without conscious association to 
symptoms. The high incidence of smoking initiation prior to the onset of active psychosis could 
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suggest a mechanism driving increased smoking vulnerability that precedes the full transition to 
SCZ. In general, the majority of smokers begin the habit in adolescence, a period prior to the 
emergence of most SCZ symptoms. For example, a study of 237 smokers with SCZ found that 
86% of subjects began smoking more than a year prior to disease onset, with a mean age of 18.7 
years at smoking initiation and 24.1 years at onset of psychosis (Beratis et al. 2001). A longitudinal 
study of males screened in late adolescence and early adulthood found that individuals who 
smoked 10 or more cigarettes per day as teens were 2.28 times more likely to be later diagnosed 
with SCZ, further suggesting a higher rate of smoking prior to the emergence of symptoms (Weiser 
et al. 2004). However, some evidence suggests that smoking initiation may overlap with the 
prodromal phase of SCZ, a period preceding psychosis by weeks to years. During the prodromal 
phase, individuals typically first experience symptoms such as depression, anxiety, and social 
withdrawal, followed by brief, infrequent, and mild thought disturbances and predelusions prior to 
psychosis (Larson et al. 2010). Interestingly, some evidence suggests that individuals with SCZ 
start smoking closer to symptom onset than smokers diagnosed with nonpsychotic mental illness, 
which could imply an overlap in smoking initiation and prodromal syndrome (Riala et al. 2005). 
A study of NIC use in young people designated as ultrahigh-risk (UHR) for psychosis, a formal 
classification of prodromal syndromes, found that 46% of UHR subjects were smokers, compared 
to 22% of age-matched controls. Additionally, UHR subjects reported significantly more frequent 
use of NIC than controls (Gupta and Mittal 2014). While the majority of evidence indicates that 
individuals with SCZ begin smoking prior to the full emergence of psychosis and are more likely 
to smoke than controls, it is unclear if this is driven by prodromal symptoms or is the result of an 
intrinsic vulnerability to both SCZ and NIC dependence. 
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1.3  SMOKING AS SELF-MEDICATION IN SCHIZOPHRENIA 
The “self-medication hypothesis” theorizes that individuals with SCZ smoke at an 
increased rate in order to normalize symptoms of the disease or alleviate side effects of 
antipsychotic drugs (APDs) (Leonard et al. 2002). As previously mentioned, this may not be 
mutually exclusive from a “reinforcement hypothesis”, as some of the features of SCZ thought to 
motivate smoking, such as reward dysfunction and anhedonia, could also be potentially alleviated 
by NIC intake. SCZ is characterized by several general domains of symptoms. Positive symptoms 
encompass elements of psychosis, such as hallucinations and delusions, while negative symptoms 
refer to a reduction in volition leading to a lack of motivation, reduction in speech, and social 
withdrawal. Changes in neurocognition are also prominent, such as difficulties with memory, 
attention, and executive function, as well as previously described affective symptoms, such as 
anhedonia (van Os and Kapur 2009). While the neurobiology of SCZ is not fully understood, there 
is a great deal of established knowledge about circuit pathologies associated with these changes, 
many of which reflect a general alteration in the balance of excitation and inhibition throughout 
regions of the brain (Ferguson and Gao 2018; Gao and Penzes 2015) 
 Positive symptoms are largely attributed to increased activity of ventral tegmental area 
(VTA) DA neurons, the firing patterns of which affect DA release in numerous efferent targets 
throughout the brain. DA signaling from VTA to NAcc is critical for attributing appropriate 
salience to relevant cues and stimuli based on sensory input and prior expectations. Briefly, 
hyperresponsivity of the mesolimbic DA system produces an increase in background DA activity 
and a  decreased “signal to noise ratio” in encoding relevant stimuli, contributing to hallucinations 
and delusions (Sterzer et al. 2018; Kapur 2003).  Imaging studies show increased DA synthesis as 
well as increased synaptic DA in the mesolimbic pathway during psychosis (Howes et al. 2012). 
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This disruption also contributes to impairments in sensory gating widely observed in SCZ patients 
and first-degree relatives. Sensory gating refers to a neurological process of filtering out 
unnecessary or redundant stimuli from all perceived environmental stimuli and is reflected in 
measures such as inhibition of the auditory startle response by presentation of a brief prepulse 
stimulus (Swerdlow et al. 2016). Additionally, dysfunction in DA signaling of relevant stimuli 
also reduces their motivational salience, producing changes in reward-associated learning. 
Concurrently, changes in glutamate and DA signaling as a result of receptor feedback reduce 
prefrontal cortical DA release and contribute to deficits in working memory, attention, and 
executive function (Slifstein et al. 2015). Together, these alterations are hypothesized as a 
mechanism underlying certain aspects of both negative and cognitive symptoms of the disease, as 
this frontal-striatal connection is necessary for meaningfully translating reward-associated striatal 
DA signals to guide motivated behaviors (McCutcheon et al. 2020; Howes et al. 2012). Negative 
symptoms affecting reward have an overlapping impact on cognitive functioning, as motivation, 
effort allocation, and value representation are active processes in many cognitive demands 
(Robison et al. 2020). A number of studies have indicated that severity of negative symptoms, 
cognitive impairments, and psychosocial functioning are strong predictors of overall patient 
outcome in SCZ, which highlights the need to understand and effectively manage these symptoms 
(Milev et al. 2005; McGurk et al. 2000). While antipsychotic drugs (APDs) have been available 
for decades, efforts to develop successful pharmacotherapies to mitigate cognitive dysfunction in 
SCZ have been largely unsuccessful (Goff et al. 2011).  
Much of the research behind the self-medication hypothesis proposes that the action of NIC 
on 7 nicotinic acetylcholine receptors (nAChRs) throughout the brain provides a pro-cognitive 
effect. Associations of nicotinic function with cognitive effects are behaviorally supported by wide 
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evidence of NIC administration enhancing cognitive performance in both smoking and 
nonsmoking controls (Heishman et al. 2010). Interest in the relationship of 7 nAChRs and SCZ 
grew from several converging lines of neurobiological, behavioral, and genetic findings. 
Polymorphisms and partial duplication of CHRNA7, the gene for the 7 nAChR subunit, have 
been associated with SCZ diagnosis and disease-related deficits, including impaired prepulse 
inhibition of startle (PPI) and visual information processing, as well as smoking prevalence 
(Bakanidze et al. 2013; Stephens et al. 2012; Leonard et al. 2007) Critically, a significant 
correlation between neuropsychological performance (measured by the Wisconsin Card Sorting 
Task) and PPI deficits, which are largely considered two distinct domains, has been demonstrated 
specifically in SCZ smokers but not nonsmokers (Rabin et al. 2009). This may suggest a unique 
mechanistic link between NIC use and both cognitive and sensorimotor gating deficits in SCZ. 
A test of the hypothesis that individuals with SCZ smoke as a means of self-medication 
can be approached from multiple directions. An intuitive question is whether symptoms are more 
or less severe in patients who smoke, as a potential indication of NIC intake reducing symptom 
severity. Alternatively, this relationship could be examined from the reverse: are individuals with 
more severe symptoms smoking more? Many studies suggest an association between smoking 
status, greater severity of negative and cognitive symptoms, and poorer outcomes (Iasevoli et al. 
2013; Reed et al. 2016). A 2007 study of SCZ outpatients examining the relationship between 
PANSS (Positive and Negative Syndrome Score) scores and level of NIC dependence found 
significant associations between the two. Specifically, high total PANSS scores, indicating more 
severe symptoms, were significantly more likely in highly dependent and nonsmoking patients 
than in mildly dependent smokers, but that scores of negative symptoms, which are often 
associated with the self-medication hypothesis, were not associated with NIC dependence. Highly 
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dependent smokers also had the greatest proportion of lifetime hospital admissions (Aguilar et al. 
2005). A community mental health study of individuals with SCZ found no association between 
smoking severity (i.e. cigarettes smoked per week) and scores of positive and negative psychiatric 
symptoms, though this study did not include any assessment of cognitive function (Dixon et al. 
2007). A  larger study of multiple diagnostic groups found that SCZ patients were more likely than 
any other group to smoke heavily (1+ pack per day), and that greater symptom severity was 
associated with heavy smoking (Vanable et al. 2003). However, in UHR young adults, NIC use 
was associated with greater performance in several cognitive domains, suggesting that smoking 
could improve some initial symptoms, though it is unclear whether this relationship would persist 
after psychosis onset (Gupta and Mittal 2014). It is challenging to draw conclusions on the self-
medication hypothesis by examining the relationship between symptom severity and smoking 
frequency because of differing possible interpretations of the same finding. For example, higher 
levels of smoking in individuals with greater symptom severity could suggest that severe 
symptoms are driving those patients to smoke more. Conversely, the presence of severe symptoms 
in this population would also fail to support self-medication if the heavy smoking is posited to 
provide some relief of these symptoms.  
Antipsychotic drug (APD) treatment may also impact rates of smoking among individuals 
with SCZ. While a detailed exploration of APD subtypes, mechanisms of action, and relationships 
with NIC use and behavior is beyond the scope of this document, a summary of key trends is 
warranted. Broadly, APDs fall into two classes. Typical, or first-generation, APDs exert their 
action primarily through antagonism of D2 DA receptors, while atyptical (second-generation) 
APDs have greater heterogeneity in their mechanisms of action. Heavier smoking is more common 
among individuals treated with typical than atypical APDs, an observation that could lend support 
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to the anecdotal hypothesis that patients smoke to relieve extrapyramidal side effects of these drugs 
(Matthews et al. 2011; Tidey et al. 2005). Conversely, transition from a typical to an atypical APD, 
such as clozapine, has been found to reduce daily smoking, and clozapine treatment reduces NIC 
self-administration in rats, suggesting a potential effect on reinforcement (McEvoy et al. 1999; 
Abela et al. 2019). Atypical APDs have also demonstrated greater success in reducing both 
negative and positive symptoms than typical APDs, but have unique side effects that have also 
been associated with motivation to smoke (Matthews et al. 2011). Importantly, however, the high 
rate of smoking also observed in UHR individuals and first-degree nonpsychotic relatives, both of 
which experience select impairments observed in SCZ, suggests that APD side effects are likely 
not a primary driver of smoking (Ferchiou et al. 2012; Gupta and Mittal 2014). Nonetheless, 
medication status is an important variable to consider in studies of NIC use and effects in 
individuals with SCZ.  
Because of the complexity of the association between symptom severity and smoking, 
experimental studies of the acute effects of NIC administration on measurable symptoms, such as 
cognitive impairments and sensorimotor gating, are valuable in studying the self-medication 
hypothesis. However, assessment of these effects is complicated by dependence and withdrawal 
in patients who smoke. Assessing the acute effects of NIC in NIC-naïve SCZ provides insight into 
improvements that could drive continuation of NIC use prior to the development of dependence. 
Multiple studies have suggested that acute NIC administration does enhance multiple areas of 
impaired cognitive performance in SCZ nonsmokers. For example, a single dose of transdermal 
NIC improved performance on a novelty detection task of episodic memory in nonsmoking 
patients (Jubelt et al. 2008). Another study of nonsmokers with SCZ and nonpsychiatric controls 
found that administration of transdermal NIC significantly improved attentional performance on 
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the Continuous Performance Test in both groups, and improved impulsive responding to a greater 
degree in SCZ subjects (R. S. Barr et al. 2008). However, an assessment of multiple indices of 
SCZ patients’ cognitive function using the Repeatable Battery for Assessment of 
Neuropsychological Status (RBANS) before and after the use of NIC gum found improvement 
only in measures of attentional function in nonsmokers, with no benefit in smokers (Harris et al. 
2004). This suggests that acute NIC administration may provide some initial cognitive benefits to 
SCZ patients, but these effects may diminish with repeated use as tolerance develops. Multiple 
studies have also found mixed effects of NIC on sensorimotor deficits in patients, including 
improvements in smooth pursuit eye movements but a lack of effect on auditory processing 
impairments in in both smoking and nonsmoking patients (Avila et al. 2003; Sherr et al. 2002; 
Inami et al. 2007; Inami and Kirino 2019).  
Assessment of acute smoking status is imperative in interpreting measurements of 
cognitive and sensorimotor function before and after experimental NIC administration. Findings 
of baseline performance and NIC effects can vary greatly depending on whether smokers are 
assessed after normal smoking or during early withdrawal, which can begin within several hours 
of their last cigarette. This is key to understanding whether pro-cognitive effects of NIC observed 
in nonsmoking patients are present in smokers as well, or whether relative improvements in 
performance after smoking are a result of a “return to baseline” through relief from withdrawal-
related impairments. Meta-analyses do provide some evidence that cognition-enhancing effects of 
acute NIC in control subjects may persist regardless of smoking status, but findings in patients are 
mixed (Heishman et al. 2010). When administered NIC through smoking or nasal spray prior to 
testing, SCZ smokers demonstrate increased levels of auditory PPI relative to both SCZ 
nonsmokers and briefly deprived smokers, indicating that the positive effects of acute NIC on PPI 
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can persist even after chronic smoking (Kumari et al. 2001; Woznica et al. 2009; Hong et al. 2008). 
However, similar studies suggest that improvement of PPI or MMN deficits by NIC administration 
in SCZ smokers may be limited due to a greater baseline impairment when measured after 
abstinence (George et al. 2006; Inami and Kirino 2019). Additionally, a finding of improved spatial 
working memory and attention in SCZ smokers after smoking may be more indicative of 
abstinence-induced exacerbation of these impairments than of the benefit of NIC administration 
(Sacco et al. 2005). 
Though the effects of smoking on cognitive and sensorimotor gating deficits have been 
heavily studied as a means of examining the self-medication, studies directly assessing patients’ 
motivations for smoking are a far less common, but useful, source of insight. These few 
reports suggest that addictive effects, anxiety, and reduction of negative symptoms are the 
most highly rated reasons for smoking among surveyed SCZ smokers (Gurpegui et al. 2007; 
Forchuk et al. 2002). Additionally, patients were more likely to cite stimulation and 
sensorimotor manipulation as motivators of smoking when compared to nonpsychiatric control 
smokers, though anxiolytic and addictive effects were more highly reported overall (A. M. Barr 
et al. 2008). These outcomes suggest potential, and possibly interacting, roles of both the 
reinforcement and self-medication hypotheses in driving high rates of smoking in SCZ. 
1.4 STUDIES OF NICOTINE IN PRECLINICAL MODELS OF SCHIZOPHRENIA 
 Although SCZ is a disease distinct to humans, study of its pathophysiology in animal 
models is a valuable tool. SCZ is defined by its symptoms, as a clear understanding of 
underlying causes and pathology of the disease is lacking. Translational models of SCZ allow 
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for direct modeling of putative etiological factors, pathophysiological phenotypes observed in 
SCZ, and experimental study of behavioral outcomes. Thus, while there is no “ideal” animal 
model of SCZ that captures the full spectrum of related behavioral symptoms and known 
biological features, the goal of any model is to allow for the association of known 
neurobiological features of the disease with measurable behavioral parallels of symptoms in 
order to inform more effective treatment (Jones et al. 2011). Similarly, cigarette smoking is 
also unique to humans, but studies of NIC self-administration in animals have provided great 
insight into the reinforcing effects of NIC, as well as behavioral and biological factors that 
influence NIC use (O’Dell and Khroyan 2009). In both cases, animal models allow for a degree 
of control of factors such as age, sex, rearing environment, and drug exposure in experiments 
that is not feasible in clinical studies. Preclinical studies also circumvent challenging ethical 
limitations and expand the possibilities of experimental manipulation, as clinical studies 
ethically could not induce neurodevelopmental insult, perform invasive procedures to study 
SCZ neuropathology, or initiate regular NIC use in subjects. Animal models of psychiatric 
disease and drug abuse are therefore critical tools that further inform discoveries in clinical 
study.  
A high priority in the preclinical study of NIC in SCZ is the use of an animal model that 
best captures known elements of disease pathophysiology as well as measurable and relevant 
behavioral and neurophysiological endpoints thought to be impacted by NIC intake. The majority 
of preclinical studies of NIC in SCZ models have focused on the “self-medication” model, 
exploring the effects of NIC and nicotinic drugs on SCZ-related behaviors and endophenotypes. 
For example, in adult offspring of dams treated with lipopolysaccaharide (LPS) during pregnancy, 
known as the maternal immune activation (MIA) model of SCZ, repeated administration of NIC 
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has been shown to reduce deficits in PPI and selective attention (Waterhouse et al. 2016). 
Subchronic treatment with ketamine induces severe disruption of prefrontal inhibitory activity and 
resulting cognitive impairments paralleling observations in SCZ, making ketamine treatment 
another popular rodent model of SCZ (Frohlich and Van Horn 2014). Treatment with NIC has 
been shown to normalize deficits in working memory (Rushforth et al. 2011) and multisensory 
integration (Jacklin et al. 2012) in ketamine-treated rats. However, preclinical studies exploring 
NIC reinforcement in animal models of SCZ are limited. A study of NIC self-administration the 
neonatal ventral hippocampal lesion (NVHL) model of SCZ suggested a modest increase in NIC 
intake among NVHL animals (Berg et al. 2014), though these results are complicated by the 
inclusion of daily administration of NIC or saline during the adolescent period. Additionally, when 
tested across a range of doses, MIA rats’ responding for NIC did not differ from controls except 
during a brief phase of acquisition using a high response requirement. Total NIC intake and 
acquisition rates were also comparable between MIA and control animals (Waterhouse et al. 2018).  
Our studies thus aimed to explore NIC reinforcement, as well as cognitive and 
neurophysiological effects of NIC, in a well-validated animal model of SCZ. The 
methylazoxymethanol acetate (MAM) rodent model is a neurodevelopmental model of SCZ that 
effectively captures numerous physiological perturbations observed in SCZ through 
administration of a mitotoxin (MAM) to pregnant dams on gestational day 17 (GD17) (Lodge 
2013). Developmental disruption at this stage selectively impacts the developing paralimbic, 
temporal, and frontal cortices, producing a SCZ-relevant endophenotype in adult offspring. MAM 
animals display measurable positive symptom analogs, such as impaired PPI and hypersensitivity 
to psychostimulants such as amphetamine (Modinos et al. 2015), as well as cognitive impairments 
such as deficits in working memory, attentional processing, and behavioral flexibility (Lodge and 
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Grace 2009). Importantly, GD17 MAM also produces an endophenotype that elegantly 
recapitulates many neurophysiological disruptions observed in SCZ. Elevated striatal DA activity 
resulting from aberrant ventral hippocampal (vHipp) drive is a hallmark of the model and a useful 
mechanistic analog of psychosis (Modinos et al. 2015). Longitudinal PET imaging in patients 
correlates elevated striatal DA activity with progression of psychosis (Howes et al. 2011), and 
multiple lines of evidence implicate altered medial temporal lobe activity in driving striatal 
hyperactivity (Grace and Gomes 2019). MAM animals also demonstrate a reduction in cortical 
and hippocampal inhibitory interneuron function, and diminished hippocampal-prefrontal 
oscillatory activity reflecting generally disrupted E/I balance and connectivity (Lodge et al. 2009; 
Lodge and Grace 2007; Lodge and Grace 2009). Despite the high face and predictive validity of 
this model, the effects of NIC in the MAM model remain largely unexplored. One study of sensory 
gating deficits in MAM animals demonstrated limited positive effects of NIC administration on 
the rodent equivalent of human auditory P50 gating (Kohlhaas et al. 2015). Additionally, systemic 
or intra-vHipp administration of an 7 nAChR agonist has been shown to normalize elevated VTA 
DA population activity in MAM animals (Neves and Grace 2018). Our work thus aimed to more 
broadly assess the behavioral and neurophysiological effects of acute and chronic NIC in order to 
evaluate possible mechanisms behind heavy smoking in SCZ.  
1.5  PURPOSE OF STUDIES 
This dissertation summarizes a series of experiments that aimed to explore two potential 
hypotheses behind increased smoking in SCZ using the MAM rodent model. In Chapter 2, I 
explore the reinforcement-based hypothesis by comparing NIC self-administration between MAM 
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and control (CTL) animals across a number of doses, as well as dissociating the primary 
reinforcing and reinforcement-enhancing effects of NIC in this model. To our knowledge, this is 
the first study examining NIC self-administration in the MAM model. The experiments of 
Chapters 3 & 4 focus on evaluating the self-medication hypothesis by assessing the effects of 
both acute and chronic NIC administration on several behavioral analogs of relevant SCZ 
symptoms and on activity of VTA DA and vHipp pyramidal neurons. In total, these experiments 
suggest that NIC is not more reinforcing in the MAM model of SCZ. However, they reveal that 
acute NIC does normalize both behavioral and neurophysiological dysfunction observed in the 
MAM model, lending potential support for smoking-induced mitigation of similar impairments in 
humans.  
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2.0 NICOTINE SELF-ADMINISTRATION IS NOT INCREASED IN THE MAM 
RODENT MODEL OF SCHIZOPHRENIA 
2.1 INTRODUCTION 
Despite success in reducing tobacco use in the general population over the last several 
decades, rates of smoking remain highly elevated among those with schizophrenia (SCZ). An 
estimated 60-80% of SCZ patients are smokers, as compared to 15-20% of the general U.S. 
population (de Leon and Diaz 2005; Dickerson et al. 2013). Smokers with SCZ smoke more 
heavily and more intensely, which contributes to negative health consequences in this population. 
Though this pattern of heavy smoking in smokers with SCZ is well-documented, no mechanistic 
explanation has yet been established. Two potential, but not mutually exclusive, hypotheses are 
that 1) nicotine (NIC), the primary reinforcing component of tobacco, mitigates some negative 
cognitive and/or sensory symptoms of SCZ, with smoking serving as a form of “self-medication”, 
or 2) SCZ confers an increased magnitude of reinforcement derived from NIC. 
Numerous clinical studies indicate that NIC administration to SCZ patients fails to impact 
positive psychotic symptoms but may be associated with improvements in cognitive deficits and 
negative symptom severity, contributing to the “self-medication” hypothesis (Smith et al. 2002; 
Beck et al. 2015). For example, one study found that both current and former smokers with SCZ 
showed higher performance in a neuropsychological assessment than SCZ “never-smokers”, while 
control subjects did not vary by smoking history (Wing et al. 2011). However, evidence of 
improvement in negative symptoms and cognitive deficits, as well as alleviation of side effects 
from antipsychotic drugs, remains mixed. Conclusive study on the effects of NIC in SCZ patients 
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is complicated by several factors including differences in the withdrawal status and antipsychotic 
drug history of patients at the time of study. Many, but not all, studies require short-term or 
overnight abstinence prior to participation, which may contribute to variability in findings on the 
effect of NIC on cognitive function. For example, smoking after acute abstinence has been 
demonstrated to improve visuospatial working memory performance among SCZ patients (George 
et al. 2002; Sacco et al. 2005). However, other research suggests that the cognitive “costs” of NIC 
withdrawal and the relative benefits of NIC consumption are not specific to a psychiatric 
population. A study by AhnAllen and colleagues found that in both control and SCZ smokers, 
switching to very low nicotine content cigarettes reduced performance on measures of smokers’ 
attention and visual processing, an effect mitigated by co-administration of NIC patch (AhnAllen 
et al. 2015). Other studies report no effects of early (1 day) or extended (3 week) NIC abstinence 
on attention or cognitive and behavioral tests in SCZ patients, suggesting NIC withdrawal may not 
have any effect on cognitive performance (Boggs et al. 2018; Hickling et al. 2018). Thus, while a 
“self-medication” hypothesis of smoking in SCZ is quite pervasive, experimental findings 
supporting this idea are limited. 
Several lines of biological and behavioral evidence lend support to the hypothesis that NIC 
reinforcement is increased in SCZ individuals. The current dopamine hypothesis of schizophrenia 
posits that alterations in dopamine function lead to impairments in appropriately ascribing salience 
to relevant stimuli, which in turn contributes to dysfunction in motivated behavior and value 
learning (Howes and Kapur 2009; Juckel et al. 2006; Whitton et al. 2015). NIC-stimulated 
dopamine responses are thought to be increased in the mesolimbic dopamine system in SCZ, 
resulting in increased NIC reinforcement (Chambers et al. 2001; Dutra et al. 2012). Additionally, 
smokers with SCZ place higher incentive valuation on cigarettes than controls and are twice as 
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likely to select smoking over alternative reinforcers, such as money or candy, suggesting a 
particular sensitivity to smoking reinforcement(MacKillop and Tidey 2011; Spring et al. 2003). 
Limited impulse control may also drive persistent smoking among SCZ patients by undermining 
attempts to abstain from reinforced smoking behavior (O’Grada and Dinan 2007). 
In addition to the broad range of clinical studies on smoking in SCZ subjects, preclinical 
work provides a valuable source of highly controlled research on the effects of NIC in SCZ and 
can address questions that cannot be approached in human subjects. Though evidence suggests 
some effect of acute NIC on cognitive performance in control animals, studies using animal models 
of SCZ have demonstrated limited support for increased cognitive or reinforcing effects of NIC in 
SCZ (Hernandez and Terry 2005; Rezvani and Levin 2001).  For example, a study using the 
maternal immune activation (MIA) model of SCZ found that MIA animals showed modest 
improvements in a working memory task after extended NIC self-administration. However, MIA 
animals did not differ in self-administration from controls, except at a single dose with a high 
response requirement (Waterhouse et al. 2018). A study by Berg and colleagues using the neonatal 
ventral hippocampal lesion (NVHL) model of SCZ found that lesioned animals self-administer 
more NIC than controls only at a moderate dose of NIC (Berg et al. 2014). These limited positive 
results are complicated by the inclusion of daily s.c. injections of saline or NIC during the 
adolescent period. NVHL rats are particularly vulnerable to stress and stress associated with these 
injections might have differentially impacted NVHL and control rats (Tseng et al. 2008). 
 Thus, the data on whether NIC reinforcement is increased in animal models of SCZ are 
limited and unclear. The present studies examined NIC self-administration, the gold standard in 
studies of NIC reinforcement, in the model of SCZ produced by prenatal administration of 
methylazoxymethanol acetate (MAM), which is arguably the most comprehensive available rodent 
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model of SCZ (Ator and Griffiths 2003; Lodge and Grace 2009). The MAM model recapitulates 
many core features observed in SCZ and, compared to other rodent models of SCZ, consistently 
shows a high degree of both construct and predictive validity (Jones et al. 2011). Importantly, 
MAM treatment on gestational day 17 (GD17) has been consistently validated in numerous 
carefully controlled experiments both within and between labs (Modinos et al. 2015; Steeds et al. 
2015; Grace and Gomes 2019).  Adult MAM animals demonstrate physiological, pharmacological, 
behavioral, and anatomical perturbations consistent with observed SCZ phenotypes including 
amphetamine and phencyclidine hyper-responsivity, disrupted prepulse inhibition of startle and 
latent inhibition, thinning of cortical limbic structures, selective loss of parvalbumin-labeled 
GABAergic interneurons of the hippocampus, and hippocampal hyperactivity, as well as resulting 
increased dopamine population activity (Lodge and Grace 2009; Grace and Gomes 2019). Because 
of the critical role of dopamine neurophysiology in reward and reinforcement, as well as the high 
construct and predictive validity of this model, the MAM model is a strong yet previously 
unexplored paradigm to study questions of NIC reinforcement.  
The following experiments thus sought to characterize NIC reinforcement in the MAM 
model of SCZ. Importantly, we aimed to study the primary reinforcing effects of NIC alone and 
in combination with its reinforcement-enhancing effects on other rewards. Although we 
hypothesized that MAM-treated rats would self-administer more NIC than control rats, the results 
show that in this model of SCZ there is no difference in NIC self-administration across a variety 
of doses and schedules of reinforcement, suggesting that SCZ pathophysiology modeled by MAM 
does not produce increased NIC reinforcement. 
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2.2 METHODS 
 Subjects. All experiments utilized Sprague-Dawley rats aged postnatal day (P)65-P75 at 
the start of experimental sessions. Rats were born in-house to timed pregnant dams (Envigo) 
injected intraperitoneally with saline (CTL; 1.0 mL/kg) or methylazoxymethanol acetate (MAM; 
25.0 mg/kg, 1.0 mL/kg) on GD17 (Lodge 2013). After weaning on P22, litters were mixed and 
pups were separated by treatment group and sex. Initial studies were performed in female 
animals as males were used for separate sex-dependent experiments, but subsequent experiments 
used both males and females to examine potential sex differences (Experiment 3). Animals were 
housed in groups of 2-3 in tub cages with woodchip bedding in a ventilated rack until the time 
of surgery (P60-P70), after which they were housed individually. Each experiment utilized pups 
from at least 2 MAM-treated (MAM) and 2 saline-treated (CTL) litters and common features of 
the MAM phenotype (cortical thinning, reduced hippocampal volume) were confirmed in adult 
littermates through postmortem histological assessment. Additionally, some adult littermates 
were used in electrophysiological experiments and displayed characteristic increases in 
dopamine neuron population activity (Grace and Gomes 2019). Animals had ad libitum access 
to water in the home cage throughout the duration of the experiment and began food restriction 
at least 48 hours prior to the first experimental session unless otherwise noted. Rats were allotted 
20 grams (males) or 15 grams (females) of chow (LabDiet Rodent 5001; LabDiet, St. Louis, 
MO) daily to maintain body weight at approximately 80% of free-feeding weight. Facilities 
were maintained on a reversed 12-hour light-dark cycle (lights off 0700), and all experimental 
procedures were carried out during the dark phase. All experiments were conducted in 
accordance with the NIH Guide for the Care and Use of Laboratory Animals and were approved 
by the University of Pittsburgh Institutional Animal Care and Use Committee. 
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Apparatus. All experimental sessions were conducted in 38 operant chambers (30.5 cm × 
24.1 cm × 21.0 cm; ENV-008CT; Med-Associates, Fairfax, VT) enclosed in sound-attenuating 
cubicles with a ventilation fan. Operant chambers were outfitted with two nosepoke holes (2.5 
cm in diameter), spaced 14 cm apart. White cue lights (3.5 cm in diameter) were located 6.25 
cm above the top of each nosepoke portal. A houselight located 1 cm below the ceiling of the 
chamber in the center of the wall containing the nosepoke portals was covered with a red filter 
sleeve except in experiments using a reinforcing visual stimulus (VS; see Experiment 3). 
Intravenous (i.v.) infusions were delivered via an infusion pump through tubing connected to 
each animal’s catheter. Tubing was protected by a flexible metal spring casing connected to a 
swivel system that allowed for largely unrestricted movement. 
Nicotine. Nicotine hydrogen tartrate salt was dissolved in 0.9% sterile saline and passed 
through a 0.22 μM filter to ensure sterility. Nicotine solutions were made every 2-4 weeks and 
stored at 4° C until experimental use. Syringes for self-administration sessions were freshly 
made each day. Doses are expressed as free base.  
Surgery and maintenance of catheter patency. Surgery was performed between P60-70. 
Rats were anesthetized using isoflurane (2%-3% in 100% O2) and implanted with indwelling 
catheters into the right jugular vein (Donny et al. 1999). Ports were capped with plastic tubing 
and flushed daily with 0.1 mL heparinized (30 U/mL) saline containing streptokinase (9.333 
U/mL) and gentamicin (66.67 mg/mL) for 5-6 days of recovery before self-administration. 
During the experimental period, catheters were flushed with 0.1 mL heparinized saline before 
and 0.1 mL heparinized saline with gentamicin (66.67 mg/mL) after each self-administration 
session. Catheter patency was confirmed via rapid loss of muscle tone after infusion of 
methohexital (5 mg/kg) following the final self-administration session at each dose and the final 
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self-administration session of each experiment. Rats that failed a patency test (1 – 4 rats per 
experiment) were excluded from data analysis. 
Self-administration sessions. Self-administration sessions took place for 1 hr daily within 
the first several hours of the dark cycle (except where otherwise noted). One nosepoke portal was 
assigned as active and resulted in the delivery of an i.v. infusion in approximately 1 second at a 
volume of 0.1 mL/kg after meeting the fixed-ratio (FR) response requirement, followed by a 60 s 
timeout period during which responses were recorded but not reinforced. As noted in each 
experiment, infusions were paired with either a neutral cue (10 s illumination of the cue light 
above the active nosepoke) or a reinforcing VS (1 s illumination of cue light, followed by 1 min 
extinction of house light and cue light). Prior studies have consistently demonstrated that rats 
will respond for the VS when presented alone, and this responding is enhanced by nicotine
(Donny et al. 2003). Conversely, rats do not respond to the 10 s illumination of the cue light 
alone, demonstrating that it is not inherently reinforcing (Rupprecht et al. 2015). It can, 
however, become a conditioned reinforcer when associated consistently with an unconditioned 
reinforcer, including long-term pairing with high doses of nicotine (Palmatier et al. 2008).  
Infusion delivery was adjusted daily for body weight. Responses at the second, inactive 
nosepoke portal were recorded but had no consequence. Left and right nosepoke portals were
randomly assigned as active and inactive. In applicable experiments, criteria for acquisition of
NIC self-administration on an FR2 schedule were an average of 5 or more earned infusions over 
a 3-day period and twice as many active responses as inactive per session during that period. 
Statistical analyses. Average responding over the final three days of each dose or 
response requirement was analyzed for each experiment; values are reported as mean ± SEM. 
ANOVA tests with repeated measures (Dose or Day, where appropriate) were followed by post-
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hoc tests (α =0.05; reported p values are adjusted for multiple comparisons using Bonferroni 
correction) comparing by Group (MAM and CTL). Data analyses were conducted in IBM SPSS 
Statistics and GraphPad Prism. 
2.3 EXPERIMENTS 
Experiment 1: Primary reinforcing effects of NIC in MAM and CTL animals. In order to 
assess primary NIC reinforcement in MAM (n = 22; 4 litters) and CTL (n = 17; 4 litters) animals, 
female rats were allowed to respond for infusions of NIC paired with a neutral cue (10-s 
illumination of cue light above active nosepoke). Rats were allowed to respond for 60 
µg/kg/infusion on a FR2 schedule for 10 days. The schedule was then changed to FR5, and nicotine 
dose was reduced every 5 days (60, 15, 7.5, 3.75 µg/kg/infusion). 
Experiment 2: Responding for NIC in extended-access sessions.  One-hour self-
administration sessions may fail to capture differences in behavior that may emerge over an 
extended period of access to NIC, as well as potential changes in self-administration over the light-
dark cycle as a result of MAM administration. To examine differences in NIC intake within 
extended access sessions and patterns of NIC-taking across the light-dark cycle, female MAM (n 
= 8; 2 litters) and CTL (n = 6; 2 litters) animals were allowed to self-administer NIC (30 
µg/kg/infusion) in 23-hr self-administration sessions (11 hr lights-off, 12-hr lights on) through 
nosepoke responding on a FR2 schedule. Animals were not food restricted and had ad libitum 
access to water and to chow pellets on a FR1 schedule via responding at a single lever on the wall 
opposite the nosepokes. Animals were returned to tub cages for one hour during the dark phase 
each day (1000-1100 h) for cleaning of operant chambers.  
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Experiment 3: Dual-reinforcing effects of NIC in MAM and CTL animals. NIC acts as a 
primary reinforcer on its own and potently enhances the reinforcing value of other rewards (Donny 
et al. 2003). Indeed, non-pharmacological stimuli accompanying NIC play a critical role in driving 
NIC self-administration and little is known about the nicotine enhancement of non-drug reinforcers 
in the SCZ population. In order to examine both primary reinforcing and reinforcement-enhancing 
effects of NIC in MAM and CTL animals, MAM (n = 9 males, 13 females, 7 litters)  and CTL (n 
= 10 males, 11 females, 7 litters) rats were allowed to respond as described above for infusions 
paired with a VS. All sessions began with the white houselight illuminated. Completion of the 
response requirement produced a 1-s illumination of the cue light above the active nosepoke portal 
followed by a complete lights-off lasting 60 s. During this time, responses at the active nosepoke 
were recorded but produced no consequence. Animals were allowed to acquire responding for VS 
paired with infusions of saline on an FR2 schedule. Dose of NIC was increased every 7 days from 
0, 3, 10, 30, 100, and 150 µg/kg/infusion. 
Experiment 4: Sucrose reinforcement in MAM and CTL animals. In order to compare 
responding for a natural reinforcer in MAM and CTL animals, female MAM (n = 12, 3 litters) and 
CTL rats (n= 14, 3 litters) were allowed to respond for 45 mg sucrose pellets (Bio-Serv, 
Flemington, NJ) in daily 1-hr sessions on FR1 (2 days), FR5 (2 days), and then FR10 (3 days) 
schedules, before completing six days on a progressive-ratio (PR) schedule of responding in which 
the response requirement increased with each successive reinforcer delivered. 
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2.4 RESULTS 
Experiment 1: MAM and CTL animals do not differ in NIC primary reinforcement across 
doses. MAM and CTL rats reliably self-administered NIC, responding more at the active portal 
than the inactive (Figure 1A). There was a significant effect of Dose (F3,35 = 8.47, p < 0.001), but 
no effect of Group (p = 0.886) and no interaction of Dose x Group (p = 0.913) in NIC self-
administration. Both MAM and CTL animals demonstrated a characteristic inverted-U dose-
response relationship but did not differ significantly in infusions earned at any dose (Figure 1B). 
MAM animals required significantly longer to meet acquisition criteria for NIC self-administration 
(8.7 ± 1.5 days versus 4.2 ± 0.6 among CTL animals, p <0.01). 
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Figure 1: Nicotine primary reinforcement is comparable in MAM and CTL animals 
(A) Average responding for NIC at the active and inactive nose-poke portals. MAM and CTL animals 
reliably acquired NIC self-administration, responding more at the active than inactive nose-poke. (B) 
Average infusions earned by MAM and CTL rats at each NIC dose. Data points express the mean number 
of infusions earned over the last three sessions at each dose. MAM and CTL animals did not differ 
significantly at any dose tested. CTL, control; MAM, methylazoxymethanol acetate; NIC, nicotine. 
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Experiment 2: MAM and CTL animals do not differ in NIC self-administration in an 
extended-access paradigm. Compared to CTL rats, there was no impact of MAM on nicotine self-
administration in 23-h extended access sessions (Figure 2A-B). There was no significant effect of 
Day (F20,251 = 1.085, p = 0.37) or of Group (F1,251 = 0.91, p = 0.34) on mean infusions earned. 
Additionally, MAM and CTL rats did not differ in patterns of responding within each session 
(Figure 2C). Within the light-dark cycle of a single session, there was a significant effect of Light 
on responding (F1, 24 = 31.26, p <0.001), as both MAM and CTL animals responded markedly less 
during the light phase. MAM and CTL animals did not differ in mean food pellets earned per 
session over the final three experimental sessions (MAM = 535.0 ± 15.0, CTL = 548.6 ± 7.6 pellets; 
p = 0.18). 
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Figure 2: MAM and CTL animals do not differ in self-administration over an extended access period 
(A) Average responding for NIC at the active and inactive nose-poke portals over each 23-hour session. Both 
MAM and CTL animals reliably responded more at the active than inactive portal. (B) Average infusions earned 
across all 23-hour access sessions. MAM and CTL animals did not differ significantly in the number of infusions 
earned in each session across the 21 days of self-administration. (C) Representative infusion data for a single 
23-hour access session (day 17). Each row of data points represents the infusions earned by one rat across the 
23 hours of self-administration, wherein each point is a single infusion. Shaded boxes represent the dark phase 
of the session. MAM and CTL animals did not demonstrate any differences in patterns of responding across the 
23-hour access period.  
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Experiment 3: MAM animals of both sexes respond less for NIC paired with a reinforcing 
VS. Both male and female MAM rats responded less than controls for NIC paired with a mildly 
reinforcing light stimulus (Figure 3). There was a significant effect of Group (F1, 242 = 40.74, p < 
0.001) and of Dose (F4, 242 = 47.11, p < 0.001), as well as a Group x Dose interaction (F4,242 = 4.88, 
p < 0.005). There was no effect of Sex (p = 0.155) or interaction of Sex x Group (p = 0.88), Sex x 
Dose (p = 0.66), or Sex x Group x Dose (p = 0.91).  MAM animals earned significantly fewer VS 
presentations than CTL animals when paired with saline or with 3, 10, 30, or 150 μg/kg nicotine 
infusions (ps < 0.05). There was no effect of Sex (p = 0.25), Group (p = 0.71), or Sex x Group (p 
= 0.40) on days to meet acquisition criteria. Across doses, MAM and CTL animals made an 
average of 5 or fewer inactive nosepoke responses per session and at least twice as many active as 
inactive responses. 
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Figure 3: CTL animals self-administer more NIC infusions + VS than MAM animals 
Average infusions + VS earned by MAM and CTL rats of each sex at each NIC dose. Data points express 
the mean number of reinforcers earned over the last three sessions at each dose. CTL animals earned 
significantly more reinforcers than MAM animals at 0 µg/kg/inf (*p < .05), 3 µg/kg/inf (+p < .005), 10 
µg/kg/inf (#p < .001), and 30 µg/kg/inf (#p < .001), but did not differ significantly at 100 µg/kg/inf (p = 
.164). There was no effect of sex at any dose (p = .611). 
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Experiment 4: Sucrose reinforcement is reduced in MAM animals. Average responses for 
sucrose pellets on a PR schedule of reinforcement over the final three days of the experiment were 
compared between MAM and CTL animals. MAM and CTL animals made comparably low (<15) 
inactive responses per session, but MAM animals responded significantly less than CTL animals 
at the active nosepoke (t24 = 2.25; p < 0.05, unpaired t-test; Figure 4) and reached lower 
breakpoints, suggesting that sucrose rewards are less reinforcing to MAM rats than CTL. 
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Figure 4: MAM animals respond significantly less for sucrose rewards than CTL animals 
Average active and inactive responding for sucrose pellets on a progressive ratio schedule of reinforcement. 
Bars represent average responses made over the final 3 days of testing. CTL animals responded significantly 
more than MAM animals at the active nose-poke (t30 = 2.19; p < .05; significant difference indicated by *). 
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2.5 DISCUSSION 
The primary reinforcing action of NIC is not increased in the MAM model of SCZ. The 
present study utilized the MAM model of SCZ, which is arguably the most comprehensive rodent 
model of SCZ currently available35,36, to study nicotine reinforcement. The results of our 
experiments demonstrate that MAM-treated rats do not differ from controls in the primary 
reinforcing effects of NIC. Both groups responded comparably for NIC across a range of doses in 
1-hr sessions. Moreover, when rats were allowed to self-administer NIC in 23-hr access sessions, 
MAM-treated and CTL animals did not differ in infusions earned across sessions or in their 
patterns of responding across the light-dark cycle within each session. These findings suggest that 
E17 MAM administration does not promote increased NIC intake in both short and long access 
periods. 
Combined primary reinforcing and reinforcement enhancing effects of NIC are reduced in 
MAM-treated animals. In the presence of non-NIC reinforcers, NIC self-administration is driven 
by the combined actions of NIC as a primary reinforcer, as well as its enhancing effects on 
reinforcement from other rewards. In our experiments, MAM rats responded significantly less for 
NIC paired with a reinforcing VS relative to controls across several NIC doses, a measure that 
reflects a reduction in the combined primary reinforcing and reinforcement enhancing effects of 
NIC. However, comparing the reinforcement enhancing action of NIC between MAM-treated and 
CTL rats is complicated by the observation that MAM-treated animals responded less than controls 
for VS reinforcers even in the absence of nicotine. The reinforcement enhancing effect of NIC is 
correlated with the reward strength of the reinforcer that is enhanced. Thus, one potential 
interpretation of these results is that NIC reinforcement enhancement, like primary reinforcement, 
is similar between MAM-treated and CTL animals, as MAM-treated animals responded less for 
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VS alone but showed a proportionally similar magnitude of enhanced responding when reinforcers 
were delivered with NIC. Additionally, while previous studies have reported small sex differences 
in self-administration at certain NIC doses, key differences in design between those and the present 
study may account for the lack of sex differences observed here (Rupprecht et al. 2015).   
Reinforcing effects of NIC relative to other rewards in MAM-treated animals. The reduced 
level of responding for VS or sucrose among MAM animals suggests features of anhedonia 
consistent with those observed in SCZ (Whitton et al. 2019). In contrast, MAM and CTL animals 
responded comparably for NIC alone. This might suggest that NIC is more reinforcing than other 
rewards to MAM-treated animals, but is not more reinforcing in MAM-treated rats compared to 
CTL animals. Indeed, there is an observed relationship between severity of anhedonia and smoking 
status in SCZ, and many SCZ smokers cite positive affective effects of NIC particularly when they 
are feeling “low” (Khantzian 2016; AhnAllen et al. 2012). Interestingly, other studies employing 
the MAM model have found inconsistent results in reward-related behavior. One study found that 
MAM-treated rats consistently pursued the highest reinforced option in a behavioral flexibility 
task, and made fewer perseverative choices compared to CTL animals (Kaneko et al. 2017). 
Though this reported reduction in perseverative behavior is counter to previous observations in 
MAM-treated animals, the tendency to choose the more highly reinforced option may suggest an 
increased sensitivity to natural rewards (Gastambide et al. 2012). While there are no previous 
reports of NIC self-administration in MAM-treated animals, a study by Ruda-Kucerova and 
colleagues demonstrated that MAM-treated animals did not differ from controls in 
methamphetamine self-administration, despite a link between SCZ and methamphetamine use in 
clinical populations (Ruda-Kucerova et al. 2017). It is important to note, however, that complex 
variables beyond reward, such as stress and environmental factors, likely interact with 
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neurobiological factors to influence smoking in SCZ patients, and should be considered when 
studying the issue as a whole (Prochaska et al. 2017) 
Studies of NIC in other animal models of SCZ. Although this is the first study of NIC self-
administration in the MAM rodent model of SCZ, published studies using other rodent models of 
SCZ report mixed results. The NVHL model, for example, was found to produce a modest increase 
in responding for a moderate dose of NIC + VS, but not higher or lower doses, and an increase in 
responding during extinction and reinstatement of NIC + VS self-administration (Berg et al. 2014; 
Rao et al. 2016). NIC self-administration did not improve performance in a spatial learning and 
working memory task in NVHL or sham animals, suggesting a lack of cognitive effect (Berg et al. 
2014). However, these studies are potentially confounded by the stress of repeated injections 
during adolescence prior to NIC self-administration. Conversely, pharmacological models of SCZ 
such as phencyclidine (PCP) administration and amphetamine sensitization, which aim to capture 
elements of hyperglutamatergic and hyperdopaminergic states in SCZ respectively, consistently 
failed to increase NIC self-administration in rats, and have even demonstrated a reduction in NIC 
+ VS self-administration relative to controls (Fletcher et al. 2018; Swalve et al. 2015). Moreover, 
while the MIA model also did not alter NIC self-administration, NIC self-administration did 
mitigate cognitive deficits observed in MIA animals, lending further support for a self-medication 
hypothesis (Waterhouse et al. 2018). Additionally, mice with a mutation commonly observed in 
human SCZ patients in CHRNA5, which codes for the 5 subunit of the nicotinic receptor, 
demonstrated cortical hypofunction that could be normalized with chronic NIC delivery (Koukouli 
et al. 2017). This diversity of findings may reflect differences in the elements of SCZ 
pathophysiology captured by each particular model and their impact on the effects of NIC, as well 
as limitations in certain experimental designs. The MAM model is distinct from other animal 
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models of SCZ in its encapsulation of behavioral, anatomical, pharmacological, and physiological 
perturbations observed in the disease, namely those of the midbrain dopamine system, achieved 
through neurodevelopmental disruption. The overall impression conferred by our findings in the 
MAM model as well as those in observed in several different models of SCZ is that NIC self-
administration is not consistently or robustly exaggerated, in contrast to the increased smoking 
seen among SCZ patients. These findings are consistent with the hypothesis that the reinforcing 
effects of NIC are not altered in SCZ. Thus, this suggests that increased smoking is not driven by 
increased NIC reinforcement but rather by another motivating factor, such as improved cognitive 
or social functioning, that is not captured in animal self-administration studies.  
Differences in valuation of cigarettes vs. non-NIC rewards observed in SCZ smokers. The 
findings of our experiments align with some aspects of NIC use and smoking in human SCZ 
patients. While we did not observe increased NIC intake among MAM-treated animals, which 
would parallel heavier smoking in SCZ patients, our results reflect a difference in the relative 
valuation of NIC vs. non-NIC rewards that may also be observed clinically. Studies of human 
patients completing tasks to earn chocolate rewards have also suggested that observed deficits in 
goal-directed learning are not due to insensitivity to reward value or reward prediction error  
(Morris et al. 2018). However, studies of SCZ smokers have suggested a specific overvaluation of 
cigarette reinforcement. SCZ smokers report greater hedonic response to NIC than control 
smokers, and SCZ smokers select cigarettes over alternative reinforcers twice as often as controls 
in a hypothetical choice task (Spring et al. 2003; Tidey 2016). Such findings provide an alternative 
hypothesis to the notion that smoking serves as a form of “self-medication” of aberrant sensory 
and cognitive symptoms and has more robust pro-cognitive effects in SCZ than in controls, which 
has also been challenged by direct studies (Hahn et al. 2013). Thus, our results in the MAM model 
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may parallel differences in the valuation of cigarettes relative to other reinforcers observed in 
human subjects to some degree, though direct evaluation of reinforcing efficacy could be better 
studied through experiments assessing elasticity of demand or choice procedures between NIC and 
other reinforcers. Regardless of experimental approach, however, concomitant use of antipsychotic 
drugs in patients within human studies is an additional difference between clinical and preclinical 
results, as varying side effects of these drugs could influence NIC effects, including reinforcement 
(Wijesundera et al. 2014). 
Final conclusions. Overall, these findings suggest that SCZ pathophysiology, as modeled 
by E17 MAM administration, does not produce an increase in NIC reinforcement. To the extent 
that MAM-treated rats are a valid model of SCZ, these results suggest that increased NIC 
reinforcement does not account for increased smoking in SCZ patients. Despite modeling many 
neurobiological aspects of SCZ, the MAM model fails to recapitulate SCZ entirely, and thus, 
alternatively, could fail to capture a specific biological or symptomatic feature that would increase 
NIC reinforcement. While our results do not directly follow the increased smoking observed in 
clinical SCZ populations, the differences observed in MAM-treated animals’ responding for NIC 
relative to other rewards may have relevant implications. Smokers with SCZ are a vulnerable sub-
population that may be differentially affected by tobacco control policies, such as mandated 
reduction of NIC content in tobacco products, and a more thorough understanding of NIC 
behavioral pharmacology in this population would be helpful in informing proposed policies. 
Further clinical study is necessary to better understand motivators and outcomes of smoking in 
SCZ, which can be supplemented by preclinical exploration of mechanistic solutions.  
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3.0 NICOTINE MITIGATES SOME COGNITIVE IMPAIRMENTS IN THE MAM 
MODEL OF SCZ 
3.1 INTRODUCTION 
An elevated rate of smoking among those with schizophrenia (SCZ) remains a persistent 
issue contributing to discrepancies in health and quality of life. Despite long-established 
knowledge of this high incidence, the mechanism driving this particularly heavy smoking remains 
unknown. The use of nicotine (NIC), the primary reinforcing component of tobacco, as a form of 
self-medication among SCZ smokers is one prevailing hypothesis. Anecdotally, this self-
medication hypothesis was long associated with relief of antipsychotic drug side effects (Goff et 
al. 1992). However, elevated rates of tobacco use are observed before psychosis onset and when 
medication status is controlled for, challenging this explanation as a primary motivator of heavy 
smoking (Ward et al. 2019; de Leon and Diaz 2005). A great deal of research has also focused on 
the direct effects of NIC on sensory gating and cognitive impairments in SCZ, with the hypothesis 
that smoking provides some relief of SCZ-related dysfunction, which drives continued tobacco 
use (Kumari and Postma 2005). 
In order to explore the validity of the self-medication hypothesis, many studies have 
attempted to assess the effects of NIC on measures of cognitive dysfunction in SCZ patients. 
Comparison of cognitive symptom severity in SCZ smokers versus nonsmokers may not be an 
ideal metric to inform the self-medication hypothesis, as one cannot determine whether being a 
smoker impacts cognitive status, or if those with more severe symptoms are more likely to smoke 
(Wing et al. 2011; Taiminen et al. 1998). Because of this, experimental assessments of NIC effects 
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on cognition in both smokers and nonsmokers are valuable. Acute transdermal NIC administration 
can improve attentional performance, response inhibition, and episodic memory in SCZ 
nonsmokers (R. S. Barr et al. 2008; Jubelt et al. 2008). Cigarette smoking has also been 
demonstrated to improve visuospatial working memory (VSWM) performance in SCZ smokers, 
while acute smoking abstinence selectively exacerbates impairments in this group (Sacco et al. 
2005; George et al. 2002). Differences in the effects of NIC on attention in nonsmoking versus 
smoking subjects may suggest a development of tolerance or desensitization to its cognition-
enhancing effects. For example, NIC gum selectively improved attention in nonsmoking, but not 
smoking, SCZ patients, with no effects on any other cognitive domains assessed using the testing 
battery (Harris et al. 2004). Conversely, however, assessments of attentional performance in 
studies comparing controls and SCZ patients suggest that NIC improves attention in both SCZ 
smokers and nonsmokers, while only nonsmoking controls demonstrate NIC-induced 
improvements (R. S. Barr et al. 2008; Sacco et al. 2005). These findings illustrate the importance 
of considering effects of acute NIC administration in both nonsmokers and smokers, as well as the 
effects of acute smoking abstinence, in clinical studies of cognition. 
Experimental NIC administration also consistently improves sensory gating deficits in SCZ 
subjects. Sensory gating is a key neurological process that functions to filter redundant or 
unnecessary stimuli from higher cortical processing, effectively preventing an excess of irrelevant 
environmental stimuli. Deficits in sensory gating measured by assessments such as tactile or 
auditory prepulse inhibition of startle (PPI) or specific auditory evoked potentials (AEPs) in 
response to successive stimuli are a reliable clinical marker of SCZ. This complex mechanism 
arises from a precise balance of excitatory and inhibitory signaling throughout multiple brain 
regions, including hippocampus, thalamus, and prefrontal cortex (Swerdlow et al. 2016). The 
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severity of these deficits may therefore be associated with other cognitive symptoms of the disease, 
as they are indicative of a wider systemic impairment of inhibition and filtering of unnecessary 
stimuli (Xia et al. 2020). NIC administration consistently enhances auditory and tactile PPI in both 
control and SCZ smokers and nonsmokers, suggesting a direct pharmacological effect of NIC 
rather than a reversal of withdrawal-induced deficits (Postma et al. 2006; Kumari et al. 1997; Hong 
et al. 2008; Kumari et al. 1996). When measured under conditions of smoking satiation, SCZ 
smokers were comparable to control smokers in levels of PPI, suggesting that normalization of 
PPI in SCZ is maintained by smoking (Woznica et al. 2009). Additionally, sensory gating 
impairments measured by P50 auditory evoked potentials are less pronounced in non-deprived 
SCZ smokers than in SCZ nonsmokers, suggesting that NIC may have a persistent effect on 
sensory gating in SCZ smokers (Chen et al. 2011). In fMRI studies, NIC also improved auditory 
selective attention and decreased task-associated neuronal hyperactivity as measured by BOLD 
response in a group of SCZ mixed smokers and nonsmokers (Smucny et al. 2016). 
Importantly, a great deal of evidence implicates 7 nAChRs in regulating processes 
underlying both sensory gating and cognitive performance, an association that likely provides 
insight into the procognitive effects of NIC (AhnAllen 2012). Alterations in CHRNA7, the gene 
coding for the 7 subunit, are consistently linked with both smoking and cognitive and sensory 
gating deficits in SCZ, and 7 nAChRs are significantly reduced in several brain regions in SCZ 
(Leonard et al. 2002; De Luca et al. 2004). This receptor has been of great interest in development 
of potential therapies for these impairments in SCZ, though no compounds have proceeded 
successfully through clinical trials (Tregellas and Wylie 2019). Although 7 receptors have a 
relatively low affinity for NIC, the high blood NIC levels attained by intense patterns of smoking 
in SCZ may be particularly effective in activating these receptors.  
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Although SCZ is a distinctly human illness characterized by constructs that are not possible 
to measure in non-human subjects, animal models capturing aspects of the disease are useful in 
developing a mechanistic understanding of symptoms and possible treatments. Studies in animal 
models allow for a degree of control over factors such as drug history, smoking status, and lifestyle 
that is difficult or impossible to achieve with human subjects. Additionally, studies in animal 
subjects allow researchers to pursue invasive or potentially risky approaches that would be 
ethically challenging in clinical studies. While animal models can vary widely in induction method 
and resulting phenotypes, preclinical studies of the effects of NIC and nicotinic agonist drugs on 
cognitive performance have thus far yielded results largely parallel to those in clinical studies. 
Both NIC and 7 agonists have been shown to enhance performance on cognitive flexibility and 
reversal learning phases of the attentional set-shifting task (ASST) in control rats, though studies 
of drug effects on this task in model animals are limited (Allison and Shoaib 2013; Wood et al. 
2016). Chronic NIC, both self-administered and experimenter-administered, normalized PPI and 
improved latent inhibition, a measure of selective attention, in the maternal immune activation 
(MIA) rodent model of SCZ (Waterhouse et al. 2016; Waterhouse et al. 2018). Additionally, acute 
administration of NIC normalized deficits in a novel multisensory integration task in rats treated 
with ketamine, a common pharmacological model of SCZ (Cloke et al. 2016). However, acute 
NIC produced only modest improvements in performance of the radial-arm maze task in the 
neonatal ventral hippocampal lesion (NVHL) model (Berg et al. 2014). Variation in findings across 
different assessments, NIC administration schedules, and animal models illustrate the need for the 
study of both acute and chronic effects of NIC on a range of tasks in a well-validated model of 
SCZ.  
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The methylazoxymethanol acetate (MAM) rodent model of SCZ is a neurodevelopmental 
disruption model with high predictive and face validity (Lodge and Grace 2009). Administration 
of MAM on gestational day (GD) 17 to pregnant rats produces reliable, measurable behavioral 
deficits in adult offspring that parallel human cognitive dysfunction seen in the disease. For 
example, offspring of MAM-treated dams, referred to herein as MAM animals, consistently 
demonstrate impairments in short-term memory as measured by the novel object recognition 
(NOR) task, as well as deficits in working memory and reversal learning in assessments such as 
the Y-maze and ASST (Featherstone et al. 2007; Lodge and Grace 2009).  Disruption of several 
measures of sensory gating have also been documented in this model, including reductions in 
auditory PPI, N40 auditory evoked potential (a rodent equivalent to the human P50 sensory gating 
response), and mismatch negativity (MMN) responses (Moore et al. 2006; Kohlhaas et al. 2015). 
To date, studies of the effects of NIC and nicotinic drugs on dysfunction in the MAM model have 
been limited. Kohlhaas et al. (2015) reported modest improvements in the N40 potential and MMN 
response in MAM animals after acute treatment with NIC or the 7 nAChR agonist drug ABT-
107 (Kohlhaas et al. 2015). Additionally, administration of both full and partial 7 agonists has 
been shown to normalize increased VTA DA population activity in MAM animals via action in 
ventral hippocampus (vHipp) (Neves and Grace 2018). This finding could suggest a potential 
mechanism through which NIC may affect behavioral impairments observed in the MAM model.     
The present studies aimed to evaluate the effects of both acute and chronic NIC treatment 
on assessments of cognitive function and sensory gating in the MAM rodent model of SCZ. These 
experiments allow the important distinction of determining how an acute dose of NIC may 
differently affect behavior in NIC-naïve subjects versus those chronically exposed to and briefly 
abstinent from NIC. This is intended to more closely model experiments of NIC effects on human 
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smokers, who may be tested after overnight abstinence as a baseline and then again after NIC 
administration. In our study, assessments were performed at both a Pre-NIC Baseline and a Post-
NIC timepoint within each group of subjects when possible. We measured auditory PPI in MAM 
and CTL rats before and after NIC administration to determine how the drug may affect sensory 
gating. In addition, the effects of NIC on episodic and working memory and cognitive flexibility 
were assessed using a NOR task and an attentional set-shifting task (ASST), which are relevant 
analogs of human behavioral tests and are well-established in the MAM model of SCZ. We 
hypothesized that acute administration of NIC, both in NIC-naïve and chronically-treated animals, 
would improve deficiencies in these measures in MAM animals relative to a Pre-NIC Baseline.  
3.2 MATERIALS AND METHODS 
Animals. All experiments utilized Sprague-Dawley rats aged 2 – 6 months at the start of 
experimental sessions. Rats were born in-house to timed pregnant dams (Envigo) injected 
intraperitoneally with saline (CTL; 1.0 mL/kg) or methylazoxymethanol acetate (MAM; 25.0 
mg/kg, 1.0 mL/kg) on GD17. After weaning on P22, pups were separated by treatment group and 
sex and housed in groups of 2-3 in tub cages with woodchip bedding in a ventilated rack. At P60-
70 (prior to the start of experiments) animals were housed individually. All experiments utilized 
both male and female animals from at least 2 MAM-treated (MAM) and 2 saline-treated (CTL) 
litters. Prior studies have found consistent behavioral deficits across both sexes in MAM animals 
(Perez et al. 2019; Potasiewicz et al. 2020). While animals of both sexes were used in each 
experiment, we did not treat sex as a variable of interest for statistical analyses. Additionally, some 
rats were tested in more than one behavioral assessment but were assigned only to Chronic NIC 
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groups in a second experiment, ensuring that all animals in Acute NIC groups were, in fact, 
receiving NIC for the first time. Animals had ad libitum access to food (LabDiet Rodent 5001) and 
water in the home cage throughout the duration of the experiment unless otherwise noted. Facilities 
were maintained on a reversed 12-hour light-dark cycle (lights off 0700), and all experimental 
procedures were carried out during the dark phase under dim red light illumination. All 
experiments were approved by the University of Pittsburgh Institutional Animal Care and Use 
Committee and were conducted in accordance with the NIH Guide for the Care and Use of 
Laboratory Animals.  
Nicotine. Nicotine hydrogen tartrate salt (MP Pharmaceuticals) was dissolved in 0.9% 
sterile saline, passed through a 0.22 μM filter to ensure sterility, and stored at 4° C with minimal 
light exposure until experimental use. Nicotine solutions were made every 2-4 weeks. A moderate 
(0.3 mg/kg, s.c.) dose of NIC was selected in order to minimize adverse effects on behavior, such 
as lethargy, while maintaining relevance to dosing in smokers (Matta et al. 2007). Animals tested 
in “chronic NIC” conditions were injected with NIC (0.3 mg/kg, s.c.) daily for 12 – 24 days prior 
to experimental testing unless otherwise noted. Those tested in “acute NIC” conditions received 
daily injections of SAL (1.0 mL/kg, s.c.) daily for at least 12 days to control for effects of repeated 
injections in the chronic NIC groups. This acute/chronic paradigm was utilized in our PPI and 
NOR experiments, but could not be followed in the ASST experiment as the progressive, multi-
session format of the task precluded study of acute NIC effects. Animals in the ASST experiment 
thus received either chronic daily NIC or chronic SAL injections for the duration of the study, 
beginning three days prior to the start of testing. 
Prepulse inhibition of startle. Assessment of auditory PPI in MAM and CTL animals was 
adapted from the protocol used by Moore and colleagues (Moore et al. 2006). Thirty minutes after 
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injection with NIC or SAL, rats were placed into transparent Plexiglas restraint tubes inside startle 
chambers (San Diego Instruments, Inc., San Diego, California) and allowed to habituate to a 
60 dB white noise background for five minutes. PPI was determined using 21 trials of a 105 
dB startle tone (40 ms in length) preceded by prepulses 7 or 11 dB above background (12 ms 
in length) with an intertrial interval of 15-25 seconds. Seven trials contained the startle tone 
alone. Startle response (measured as arbitrary force units) was measured for each trial and 
percent PPI was calculated for each prepulse intensity as a percent change in response from 
startle-only trials. Animals in both groups were tested once after SAL injection (Pre-NIC 
Baseline; 24 hr abstinent for Chronic NIC animals) and again after NIC injection (Post-NIC). 
These trials were separated by at least 48 hrs. 
Novel object recognition. Behavioral testing took place in a black Plexiglas arena (43 cm 
W x 43 cm L x 32 cm H) in a moderately illuminated testing room as described by Stark et al. 
(Stark et al. 2019). For each testing session, animals were placed in the arena with two identical 
objects placed in opposite corners and allowed to explore for five minutes (familiarization phase), 
after which they were returned to their transport cage for an inter-trial interval of 1 hour. Objects 
used were brown glass bottles, metallic cylinders, and nonporous ceramic figurines, and pairings 
of novel and familiar objects were randomized across animals. Fifteen minutes before the testing 
phase, animals were injected with NIC (0.3 mg/kg, s.c.) or SAL (1.0 mL/kg). During the testing 
phase, animals were again placed in the Plexiglas arena with one familiar object and one novel 
object (placement in corners was counterbalanced across animals) and again allowed to freely 
explore for 5 minutes. This exploration was recorded and videos were later scored for interaction 
time with each object by an experimenter blinded to subjects’ drug conditions in order to calculate 
percent interaction time with novel object ([novel time/(total interaction time)] x 100). 
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“Interaction” was defined as touching, sniffing, or orientation of the snout toward the object with 
a distance of <2 cm. Sitting on top of the object was not scored as interaction. The arena and all 
objects were cleaned with 70% ethanol between each testing period.  
Attentional set-shifting. Food restriction for attentional set-shifting (ASST) subjects began 
at least 24 hr prior to the first experimental session. Rats were allotted 20 grams (males) or 15 
grams (females) of chow (LabDiet Rodent 5001) daily after each behavioral session to maintain 
approximately 80% of free-feeding weight. Injections of SAL or NIC (0.3 mg/kg, s.c.) were 
administered 30 minutes prior to behavioral sessions. Due to the continuous nature of testing over 
a number of days, an Acute NIC condition was not possible; animals were thus assigned to Chronic 
SAL or Chronic NIC only. Testing took place in operant chambers (30.5 cm × 24.1 cm × 21.0 cm; 
ENV-008CT; Med-Associates) enclosed in individual sound-attenuating cubicles. Each chamber 
was equipped with a feeder and receptacle on one wall and a touch screen (iPad; Apple, Inc.) 
exposed by two square windows on the opposite wall. Set-shifting task sessions were run through 
K-Limbic software and touch screen responses were recorded. The progression of session criteria 
is detailed in Figure 5. Correct responses in each session were reinforced by the delivery of 20 mg 
sucrose pellets (Bio-Serv, Flemington, NJ).  
Statistical analyses. Data analyses were conducted in IBM SPSS Statistics and GraphPad 
Prism. Data from PPI and NOR experiments were analyzed using separate two-way repeated 
measures ANOVA for Acute vs. Chronic NIC animals, with Group (MAM vs. CTL) and Drug 
(Pre- vs. Post-NIC) as factors. Trials to criterion in each ASST phase were analyzed using two-
way ANOVA with Group (MAM vs. CTL) and Drug (SAL vs. NIC) as factors. Post-hoc 
comparisons were made using t-tests. Individual analyses used in each experiment are described 
in greater detail with the results of the individual experiments.  
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Figure 5: ASST session progression 
The ASST protocol consisted of four main phases depicted above. Images in each box depict possible 
stimuli presentations on the two touch screens within the operant box; correct response options for each 
phase are outlined in red. The Left & Right Training phase required 85+ correct response trials out of 96 
total stimulus presentation trials. All other phases required correct responding to 10 consecutive trials in 
order to proceed. Trials to reach this criterion (TTC) were compared between groups in the Strategy Shift 
and Reversal phases.   
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3.3 RESULTS 
PPI deficits in MAM animals are mitigated by acute or chronic nicotine administration. 
Percentage of inhibition of the startle response by 7 dB and 11 dB prepulses was measured in 
MAM (n = 13, 4 M/9 F) and CTL (n = 13, 7 M/6 F). Although MAM animals demonstrated a PPI 
deficit at both 7 dB and 11 dB prepulse intensities, only the analyses from 7 dB trial data are 
summarized here due to high variability in MAM animals’ responses at 11 dB. In the Acute NIC 
experiment, there was an effect of Group (F1,24 = 4.69,  p < 0.05) and of Drug (F1,23 = 18.52, p < 
0.0005) and a Group x Drug interaction (F1, 23 = 4.68, p < 0.05) on % PPI (Figure 6A). Post-hoc t-
tests confirmed that, at Pre-NIC Baseline, MAM animals demonstrated a significantly lower % 
PPI than CTL animals (-2.52%  9.24% vs. 27.75%  7.18%; p < 0.05). Acute NIC injection 
significantly increased % PPI in MAM animals (t12 = 4.17, p < 0.005). In the Chronic NIC 
experiment, there were no significant effects of Drug or Group or a Drug x Group interaction 
(Figure 6B). MAM (n = 12, 5 M/7 F) and CTL (n = 7, 4 M/3 F) animals did not differ in % PPI at 
Pre-NIC Baseline (24 hr abstinent from NIC) (26.60%  8.82% vs. 39.58%  8.89%; p = 0.35). 
NIC administration further increased % PPI from Pre-NIC Baseline in MAM animals (46.20%  
5.67%; p < 0.05). 
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Figure 6: Acute and chronic NIC normalizes prepulse inhibition of startle in MAM animals 
Average percent inhibition of startle response in prepulse trials (%PPI). (A) CTL animals demonstrated 
significantly higher % PPI at Baseline than MAM animals. Acute NIC normalized this difference, 
significantly increasing % PPI in MAM subjects. (B) Chronically NIC-treated CTL and MAM animals did 
not differ in % PPI at a 24-hr abstinent baseline, and NIC injection further increased % PPI in MAM 
animals. CTL rats, blue circles; MAM rats, red squares; * p < 0.05; **p < 0.01.  
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Acute and chronic nicotine normalizes novel object recognition in MAM animals. A two-
way repeated measures ANOVA of percent interaction time with novel object in drug-naïve MAM 
(n = 9, 4 M/5 F) and CTL animals (n = 8, 4 M/4 F) before and after acute NIC revealed a Group x 
Drug interaction (F1,15 = 12.05, p < 0.005; Figure 7A). At Pre-NIC Baseline, MAM animals spent 
a significantly lower percentage of time interacting with the novel object than CTL animals 
(62.70%  4.03% vs. 75.02%  1.82%; p < 0.05). However, MAM animals spent significantly 
more time interacting with the novel object after NIC administration than at Pre-NIC Baseline 
(74.07%  2.46%; p < 0.05) and were not different from CTL animals Post-NIC (68.41%  4.04%; 
p = 0.24). In the Chronic NIC experiment, there was no Group x Drug interaction and no effect of 
Group or Drug on percent interaction time with novel object (Figure 7B). MAM (n = 7, 3 M/4 F) 
and CTL (n = 7, 4 M/3 F) animals did not differ when tested after 24 hrs abstinent from NIC (Pre-
NIC Baseline; p = 0.19) or after NIC injection (Post-NIC; p = 0.65). Total object interaction times 
in both experiments were compared for MAM and CTL animals to confirm comparable 
exploration between groups. There were no significant effects of Group (p = 0.93) or Drug (p = 
0.36) and no Group x Drug interaction (p = 0.66) on total object interaction time in the Acute NIC 
experiment. In the Chronic NIC experiment, there was no effect of Group (p = 0.56) and no Group 
x Drug interaction (p = 0.76), but there was a significant effect of Drug (F1,12 = 13.51, p < 0.005). 
Total object interaction time was significantly reduced in both groups after NIC administration, 
but they did not differ at either timepoint. 
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Figure 7: Acute and chronic NIC normalizes novel object recognition in MAM animals 
Percentage of total interaction time spent with novel object during NOR task. (A) At baseline, CTL animals 
spent a significantly greater proportion of time interacting with the novel object than MAM animals. Acute 
NIC administration significantly increased MAM animals’ interaction time with the novel object to a level 
comparable to CTL animals. (B) Chronically NIC-treated MAM and CTL animals did not differ in percent 
interaction time with the novel object at a 24-hr abstinent baseline or after acute NIC administration. CTL 
rats, blue circles; MAM rats, red squares; * p < 0.05. 
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Nicotine improves strategy shifting in MAM animals but does not affect reversal learning. 
A two-way ANOVA of trials to criterion in the Strategy Shift (Figure 8A) and Reversal (Figure 
8B) phases revealed no effect of Drug or Group and no Drug x Group interaction. Despite evidence 
of impaired performance in MAM animals on reversal and set shift phases in previous versions of 
the ASST (Gastambide et al. 2012), SAL-treated MAM (n = 6, 3 M/3 F) and CTL (n = 6, 4 M/2 
F) animals did not differ in trials to criterion (TTC) in equivalent phases of this protocol. 
Interestingly, however, NIC-treated MAM animals required significantly fewer TTC (104.25  
13.89) in the Strategy Shift phase than both SAL-treated MAM animals (148.33  13.67; p < 0.05) 
and NIC-treated CTL animals (157.44  14.27; p < 0.05). These results suggest that MAM animals 
do not display measurable deficits on this version of the ASST. However, NIC administration does 
selectively improve MAM animals’ performance in the Strategy Shift phase.  
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Figure 8: Nicotine improves MAM animals' performance in the strategy shift phase of the ASST 
Mean trials required to meet progression criteria in the ASST. (A) Saline-treated MAM and CTL animals 
did not differ in performance on the Strategy Shift phase of the ASST. MAM animals treated with NIC 
throughout the experiment required significantly fewer trials to reach criterion than saline-treated MAM 
animals and NIC-treated CTL animals. (B) CTL and MAM animals did not differ in performance during 
the Reversal phase of the ASST, regardless of drug treatment. CTL rats, blue circles; MAM rats, red 
squares; * p < 0.05. 
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3.4 DISCUSSION 
Our work aims to explore mechanisms underlying increased smoking in SCZ using the 
MAM rodent model of the disease. Previously, we have demonstrated that NIC reinforcement is 
not increased in these animals, failing to support the hypothesis that SCZ pathophysiology confers 
increased NIC reward, driving continued NIC use. We therefore aimed to evaluate the self-
medication hypothesis, which proposes that NIC normalizes some cognitive symptoms of SCZ, in 
this study. These experiments sought to characterize the effects of acute and chronic NIC treatment 
on measures of sensory gating and cognitive deficits in a well-established rodent model of SCZ. 
Our findings suggest that both acute and chronic administration of NIC can normalize auditory 
gating and short-term memory deficits in the MAM rodent model of SCZ, and that chronic 
administration may improve cognitive flexibility in these animals. To our knowledge, this study is 
the first to examine the effects of NIC on these behaviors in the MAM model and is unique in its 
comparison of acute and chronic effects of the drug.  
Our study utilized auditory PPI as a measure of sensory gating in MAM and CTL rats. This 
assessment is a consistently demonstrated analog of sensory gating dysfunction in SCZ that is 
known to be mediated by nicotinic receptors and is reliably reproduced by the MAM model 
(Pinnock et al. 2015; Swerdlow et al. 1999; Ewing and Grace 2013). Our experiments confirmed 
a reduction in baseline PPI in MAM rats relative to CTL. Acute injection of NIC significantly 
increased PPI in MAM animals, fully normalizing deficits in this measure. This replicates clinical 
findings of NIC enhancement of PPI in CTL nonsmokers and parallels NIC normalization of P50 
sensory gating deficits in nonsmoking first-degree SCZ relatives (Kumari et al. 1997; Adler et al. 
1993). In order to model how chronic NIC intake may alter baseline and post-NIC PPI in smokers, 
we also tested PPI in MAM and CTL animals treated for 12+ days with NIC at a 24-hr abstinent 
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baseline and after acute NIC injection. We found that, at 24 hrs abstinent from NIC, MAM and 
CTL animals did not differ in PPI. While these were two separate experiments and thus not 
compared statistically, we did observe that these baseline levels of PPI in the chronically-treated 
animals were similar to the baseline PPI observed in saline-treated CTL rats, suggesting that this 
lack of difference likely reflects an enhancement of PPI in MAM animals rather than a reduction 
in CTL animals. Additionally, acute injection of NIC further enhanced PPI in chronically-treated 
MAM animals, suggesting that these animals did not develop tolerance to the PPI-enhancing 
effects of NIC. These findings also reflect clinical observations that acute smoking improves PPI 
in both nonpsychiatric and SCZ smokers (Hong et al. 2008; Kumari et al. 2001). However, unlike 
rats measured at 24 hrs abstinent from NIC, SCZ smokers have demonstrated exacerbated PPI 
deficits after overnight abstinence, which are also normalized by smoking (George et al. 2006). 
Nonetheless, our findings do suggest that acute NIC normalizes PPI deficits in MAM animals, and 
that this effect persists even after chronic NIC administration, potentially supporting the hypothesis 
that continued smoking in SCZ may be motivated by symptom relief. Importantly, these findings 
also validate this model as a useful tool in future studies of the effects of NIC and nicotinic drugs 
on sensory gating deficits.  
Our experiments aimed to assess the effects of NIC on episodic memory and novelty 
discrimination in the MAM model using the NOR task, a metric in which MAM animals 
consistently display deficits (Stark et al. 2019; Flagstad et al. 2005). While studies of memory 
impairments in SCZ patients are relatively complex and multidimensional, this preclinical 
assessment still holds relevance to clinical observations of impaired novelty discrimination in SCZ 
(McGuire et al. 2013). A 4-hr application of transdermal NIC prior to testing significantly 
improved performance on a novelty detection task in SCZ nonsmokers, demonstrating that acute 
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NIC treatment may mitigate episodic memory deficits in SCZ subjects (Jubelt et al. 2008). 
However, other findings suggest that NIC may only improve recognition memory performance in 
SCZ smokers, but not nonsmokers (Myers et al. 2004). Our experimental design allowed for 
assessment of acute NIC effects in modeled “nonsmoking” vs. “smoking” conditions by testing 
animals repeatedly administered saline or NIC. In animals receiving repeated injections of saline, 
we observed a significant reduction in novel object interaction time in MAM animals relative to 
CTLs, and that this difference was normalized by an acute injection of NIC. After chronic 
treatment with NIC, MAM and CTL animals did not differ in novel object interaction time at a 24-
hr abstinence baseline or when tested after acute NIC injection. In these experiments, acute NIC 
injections took place prior to the testing trial, suggesting that effects observed in testing may reflect 
an enhancement of the retrieval of object-associated memory. However, in studies of control 
animals, 7 and 42 nAChR agonists have been demonstrated to enhance novel object 
recognition when administered before the acquisition or the testing trial, suggesting that 
stimulation of these receptors may play a role in both the formation and retrieval of memories 
(McLean et al. 2016). Future experiments could provide insight into specific elements of memory 
dysfunction in the MAM model by assessing how the timing of injections may impact the observed 
effects of NIC on NOR.  
We did not observe a difference in performance of the ASST, an assessment of attention 
and cognitive flexibility, between CTL and MAM animals receiving saline injections. CTL and 
MAM animals required a similar number of trials to reach criterion in both the Strategy Shift and 
Reversal phases, despite evidence that MAM animals require more trials in these phases in other 
versions of the ASST (Gomes et al. 2014; Potasiewicz et al. 2020). The touch-screen format of 
this version of the ASST had not yet been validated in MAM animals and, based on these findings, 
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may have critical differences from prior versions. Indeed, the classic rodent ASST is a more 
multisensory assessment, as categorical shifts are made between different dimensions (i.e. textures 
and scents of digging media) in order to locate rewards (Heisler et al. 2015). This version of the 
task relies on different stimulus pairs within the visual dimension only (i.e. presentation of circle 
vs. square, left vs. right), making shifts in attention more strategy-based within a single dimension. 
Despite evidence of impaired intradimensional shifting in MAM animals in prior studies, the 
touch-screen task used in our study did not reveal a difference in performance between MAM and 
CTL animals (Gomes et al. 2014). In the traditional digging ASST format, salient stimuli of 
another sensory dimension, such as texture, are present in the testing milieu even when 
discrimination rule shifts are occurring within a single dimension, such as odor. This provides a 
greater field of perceptual features within which animals must selectively attend (Birrell and 
Brown 2000). It is thus possible that this protocol does not capture the multisensory complexity of 
prior versions, which may be necessary to detect a significant behavioral difference. Interestingly, 
we also found that NIC-treated MAM animals required significantly fewer trials to reach criterion 
in the Strategy Shift phase of our task than SAL-treated animals or NIC-treated CTL animals. This 
selective improvement observed in MAM animals was surprising, as prior studies of the ASST 
have demonstrated that repeated NIC treatment does improve performance of control rats in both 
the intradimensional and extradimensional shift phases (Allison and Shoaib 2013). It is thus 
possible that the mechanism by which NIC selectively improves performance in MAM animals 
may be specific to the model endophenotype, a possibility that can be explored in future 
experiments.  
Evaluation of the effects of acute NIC in both drug-naïve and chronically-treated animals 
was a critical and unique element of this study. In doing so, we aimed to model both baseline 
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performance and NIC effects in “nonsmokers” versus “smokers” in order to determine how 
repeated NIC exposure may change later responses within subjects. Particularly, we were 
interested in determining how chronic NIC treatment may impact behavior in the absence of NIC, 
which we measured using a 24-hr abstinent baseline. Despite evidence of exacerbated cognitive 
and sensory gating deficits in briefly- abstinent SCZ smokers due to withdrawal symptoms, we did 
not find differences in performance at the 24-hr abstinent baseline of chronically NIC-treated 
MAM and CTL animals (Harris et al. 2004; George et al. 2002). This parallels the results of a 
study by Boggs and colleagues (2018), which demonstrated that both brief and prolonged smoking 
abstinence did not affect performance of SCZ subjects on a test battery assessing multiple 
cognitive domains. Additionally, our results suggested that, in measures of PPI and NOR, the 
effects of acute NIC administration do differ between drug-naïve and chronically-treated animals. 
While chronic administration does appear to normalize baseline behavior, additional responses to 
acute NIC treatment may vary by measure, as there was no further effect of NIC on NOR in 
chronically-treated MAM and CTL animals. There are important limitations to our study as well. 
The use of a single, experimenter-administered daily dose in our chronic treatment protocol does 
not necessarily reflect human smoking, as smokers are able to self-regulate NIC intake by choosing 
when and how many cigarettes to smoke. Though MAM and CTL animals do not differ in NIC 
self-administration and thus experience similar reinforcing effects of NIC, it is likely that the 
cognitive effects we observed may differ across different dosing paradigms (Weeks et al. 
2020).Additionally, as our acute and chronic NIC treatment groups were studied in two separate 
experiments, we cannot statistically compare these groups and can only make basic overall 
comparisons. Our findings demonstrated that baseline PPI and NOR deficits in MAM animals are 
normalized by acute NIC and that chronically treated MAM and CTL animals do not differ when 
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tested at acute abstinence or after NIC. However, we cannot statistically determine that our 
observations in chronically-treated animals reflect a sustained normalization in MAM animals 
rather than a reduction in CTL animals’ performance. Future experiments could utilize different 
treatment schedules within a single experiment in order to make these comparisons possible. 
Overall, these findings suggest that NIC administration can have persistent enhancement effects 
on sensory gating and episodic memory in the MAM model, though further study is needed to 
draw conclusions on how this motivate continued NIC use in humans.  
The results of these experiments suggest that administration of a moderate dose of NIC can 
enhance measures of sensory gating, recognition memory, and cognitive flexibility in the MAM 
model of SCZ. These findings lend modest support to a self-medication hypothesis behind 
increased smoking in SCZ by demonstrating that NIC may alleviate deficits resulting from a SCZ-
parallel endophenotype. While these experiments illustrate the potential utility of the MAM model 
in further exploring nicotinic mechanisms of cognitive enhancement in SCZ, they cannot provide 
direct insight regarding how these cognitive effects of NIC may motivate patients to smoke more. 
When surveyed, SCZ smokers were not more likely than controls to cite cognitive enhancement 
as a motivator for smoking, though relief of negative affect was more consistently reported among 
patients (Galazyn et al. 2010; Forchuk et al. 2002). Additional studies suggest that healthy controls, 
but not SCZ subjects, self-report increases in concentration after acute NIC delivery (Hahn et al. 
2013) This raises the possibility that, despite many instances of cognition-enhancing effects of 
NIC in clinical studies of SCZ smokers, these effects may not necessarily improve daily 
functioning in a noticeable way. A self-medication hypothesis could thus encompass a general 
sense of “feeling better”, rather than discrete effects on cognitive performance, as a motivator for 
increased smoking in SCZ. Nonetheless, these findings offer valuable evidence linking specific 
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elements of SCZ neurophysiology modeled by GD17 MAM with relevant behavioral measures 
affected by NIC. This study adds to a body of evidence suggesting the potential of nicotinic 
agonists in improving cognitive dysfunction in SCZ. Further knowledge in this area may also 
inform more targeted approaches in reducing smoking among SCZ patients by highlighting distinct 
areas of focus for improving cessation and reducing cognitive symptoms of withdrawal. 
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4.0 NICOTINE NORMALIZES ABNORMALITIES IN DOPAMINERGIC AND 
HIPPOCAMPAL CELL ACTIVITY IN THE MAM RODENT MODEL OF 
SCHIZOPHRENIA 
4.1 INTRODUCTION 
Despite considerable progress in reducing tobacco use worldwide, disparities remain in this 
public health effort. An estimated 60% of individuals with schizophrenia (SCZ) are current 
smokers, representing roughly three times the proportion of smokers in the general population 
(Dickerson et al. 2018). This elevated rate of smoking among SCZ patients has long been 
hypothesized as an attempt to “self-medicate” negative and cognitive symptoms of the disease 
through intake of nicotine (NIC), the primary reinforcing component of tobacco (Kumari and 
Postma 2005). While direct experimental tests of whether effects of NIC on certain SCZ symptoms 
serve as a motivator of smoking have yielded mixed results, evidence does suggest consistent 
modulatory effects of nicotinic agonists on certain deficits in SCZ (AhnAllen 2012; Tregellas and 
Wylie 2019). A better understanding of motivators behind smoking and of the neurophysiological 
effects of NIC that may be unique to SCZ smokers is critical to reducing tobacco use in this 
population. Additionally, more focused study of nicotinic modulation of system dysfunction in 
SCZ could inform the development of effective pharmacotherapies.  
The majority of studies assessing the idea that smoking serves as a form of “self-
medication” in SCZ have focused on measurable behavioral effects of NIC. While findings are 
mixed, a number of studies suggest that NIC intake can acutely improve sensorimotor gating 
deficits, negative symptom severity, and some measures of cognitive function, particularly 
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attention, in patients, though this effect may vary by smoking status (Postma et al. 2006; Smith et 
al. 2002; Harris et al. 2004). Clinical studies of the neurophysiological effects of NIC underlying 
these behavioral changes are challenging due to ethical limitations, which highlights the utility of 
animal models of SCZ. While SCZ is a distinctly human disease with no precisely determined 
etiology, animal models capturing known neurophysiological disruptions observed in the affected 
brain are a versatile tool in mechanistic studies. Models developed through pharmacological 
manipulation or neurodevelopmental insult, for example, display systems-level neuronal 
dysfunction that parallel many observations in SCZ. Disruptions in functional coupling between 
prefrontal regions and its inputs are thought to contribute to negative symptoms and cognitive 
impairments and may be modulated by nicotinic activation (Pratt et al. 2008). For example, in the 
rodent chronic ketamine model of SCZ, reductions in GABAergic transmission in orbitofrontal 
cortex are linked with deficits in multisensory integration and normalized by activation of 42 
nicotinic acetylcholine receptors (nAChRs) in this region (Cloke et al. 2016). NIC administration 
has also been demonstrated to reverse hypofrontality observed in a genetic model of the disease 
by increasing inhibitory drive of interneurons in prefrontal cortex (PFC) (Koukouli et al. 2017) 
Importantly, a reduction in parvalbumin-positive (PV) inhibitory interneurons is observed 
throughout mPFC and ventral subiculum in several animal models, as well as in post-mortem tissue 
of SCZ patients (Lodge et al. 2009; Lewis and Moghaddam 2006). Evidence suggests that both 
the expression and function of PV cells, which are critical in regulating excitatory/inhibitory 
balance, are associated with nAChR function. In the hippocampus, 7 nAChRs are highly 
expressed on PV interneurons and are integral in regulating inhibitory synapses (Kawai et al. 
2002). While non-7 nAChRs play a greater role in regulating inhibitory balance in PFC, 
functional cortical 7 nAChRs are necessary in development for expression of PV interneurons in 
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this region (Lin et al. 2014; Arroyo et al. 2012). These observations elucidate a number of possible 
avenues by which NIC may affect neurophysiological function, both in SCZ and in animal models 
that effectively SCZ pathology.  
The methylazoxymethanol acetate (MAM) model is a well-validated neurodevelopmental 
disruption model of SCZ highlighted by temporal lobe dysfunction and resulting uncoordinated 
activity of ventral hippocampus (vHipp) and its downstream projection regions, including ventral 
tegmental area (VTA) and medial PFC (mPFC)(Esmaeili and Grace 2013). Reduced expression of 
PV interneurons is also observed in this model, and recent evidence suggests that 7 nAChR 
dysfunction may also be recapitulated and have key effects on system-wide neurophysiological 
disruptions (Lodge et al. 2009). One study demonstrated that 7 nAChR  agonist administration, 
either systemically or directly into vHipp, normalized elevated dopamine (DA) population activity 
observed in MAM animals but had no effect on controls (Neves and Grace 2018). This finding has 
potential implications for nicotinic effects on psychosis, which is largely thought to be a result of 
DA hyperactivity in SCZ, as well as greater systemic-wide effects. The lack of an effect in controls 
suggests that this modulatory effect may be unique to the inhibitory dysfunction observed in the 
MAM model. Additionally, the normalization of DA activity through vHipp implies a potential 
mechanism for nicotinic modulation of vHipp projections to other regions, as well as normalization 
of related behaviors such as sensorimotor gating deficits (Kohlhaas et al. 2015).  
The present experiments thus aim to address two broad questions stemming from these 
findings. Firstly, while the reported 7-mediated reduction in VTA DA hyperactivity was 
demonstrated to occur via action in vHipp, direct effects on neuronal activity in this region were 
not measured (Neves and Grace 2018). The effect of NIC on neuronal activity in vHipp and its 
downstream afferent targets remains unclear, as 7 nAChRs have a low affinity for NIC (Tregellas 
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and Wylie 2019). Additionally, prior studies did not assess the effects of a single dose versus 
multiple doses of NIC on neuronal activity, which bears relevance to human smokers and may be 
altered by changes in receptor expression or function. Therefore, the goals of this study were to 
examine the effects of both acute and chronic NIC administration on VTA DA activity, as well as 
activity of putative pyramidal cells in vHipp, in MAM and CTL animals. We hypothesized that 
NIC administration would reduce the elevated VTA DA population activity and vHipp firing rate 
observed in drug-naïve MAM animals, normalizing their activity to levels observed in CTL 
animals. We also hypothesized that this acute effect of NIC administration on VTA DA and vHipp 
activity would persist after chronic NIC treatment, but also sought to determine how baseline levels 
of activity may be altered in an acute state of abstinence. In order to explore these hypotheses, we 
conducted in vivo extracellular recordings of cells from VTA or vHipp in either drug-naïve or 
chronically NIC-treated MAM and CTL animals. We found that NIC administration, both acute 
and chronic, normalizes elevations in VTA DA and vHipp activity in the MAM model of SCZ. 
4.2 MATERIALS AND METHODS 
Animals. All experiments utilized Sprague-Dawley rats aged 2 – 6 months at the start of 
experimental sessions. Rats were born in-house to timed pregnant dams (Envigo) injected 
intraperitoneally with saline (CTL; 1.0 mL/kg) or methylazoxymethanol acetate (MAM; 25.0 
mg/kg, 1.0 mL/kg in saline) on GD17 (Lodge 2013). After weaning on P22, pups were separated 
by treatment group and sex and housed in groups of 2-3 in tub cages with woodchip bedding in a 
ventilated rack. At P60-70 (prior to the start of experiments) animals were housed individually. 
All experiments utilized both male and female animals from 2-3 MAM-treated (MAM) and 2-3 
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saline-treated (CTL) litters. Animals had ad libitum access to food and water in the home cage 
throughout the duration of the experiment. Facilities were maintained on a reversed 12-hour light-
dark cycle (lights off 0700), and all recordings were performed under white light. All experiments 
were approved by the University of Pittsburgh Institutional Animal Care and Use Committee and 
were conducted in accordance with the NIH Guide for the Care and Use of Laboratory Animals. 
Drugs. Chloral hydrate (Sigma-Aldrich) was dissolved in 0.9% sterile saline for 
intraperitoneal injection and stored at 4° C with minimal light exposure. Nicotine hydrogen tartrate 
salt (MP Pharmaceuticals) was dissolved in 0.9% sterile saline, passed through a 0.22 μM filter to 
ensure sterility, and stored at 4° C with minimal light exposure until experimental use. Nicotine 
solutions were made every 2-4 weeks. Animals in Chronic NIC experiments were injected with 
NIC (0.3 mg/kg, s.c.) daily for at least 12 days prior to recordings. Those tested in Acute NIC 
experiments received daily injections of SAL (1.0 mL/kg, s.c.) daily for at least 12 days to control 
for effects of repeated injections. Acute NIC infusions (30 g/kg, i.v.) during electrophysiological 
recording sessions were delivered through a catheter inserted into the right jugular vein. 
Surgical preparation. Rats were anesthetized with chloral hydrate (400 mg/kg, i.p., 
supplemented as necessary) and an infusion catheter was surgically placed in the right jugular vein. 
Rats were then secured into a stereotaxic apparatus and a core body temperature of 37 C was 
maintained using a thermostatically-regulated heating pad. The skull was then surgically exposed 
and the recording site prepared.   
VTA DA neuron extracellular recordings. VTA DA neuron activity was measured as 
described previously (Neves and Grace 2018). Single glass microelectrodes filled with 2% 
Chicago Sky Blue in 2M NaCl were lowered into the ventral tegmental area (AP + 5.3, ML – 0.6 
relative to bregma) using a hydraulic micropositioner. Spontaneously active neurons were 
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measured between -6.5 and -9.0 mm DV using a 30 kHz highpass filter and 16 kHz lowpass. 
Putative DA neurons meeting electrophysiological criteria of location, waveform, and firing rate 
were isolated and recorded for at least 60 s (Ungless and Grace 2012). Baseline population activity 
was determined by making 3-4 vertical passes through VTA in a random arrangement moving 
laterally and caudally, separated by 200 m each. Animals were then infused with NIC (30 g/kg, 
i.v.) and 3-4 more tracks were recorded to determine effects of systemic NIC on DA neuron 
population activity, as well as individual cells’ firing rates (Hz) and percentage of spikes in bursts.  
vHipp extracellular recordings. Extracellular recordings in vHipp were performed as 
described previously (Lodge and Grace 2007). Single glass microelectrodes filled with 2% 
Chicago Sky Blue in 2M NaCl were lowered into the ventral hippocampus (AP + 6.0, ML – 4.5 
relative to bregma) to a depth of – 6.0 to – 8.0 mm ventral of the brain surface. Spontaneously 
active neurons throughout the region were recorded for at least 120 s each in a series of tracks 
moving laterally and caudally from the first, separated by 200 m each. As described for DA 
neuron recordings, 2 - 4 vertical passes were made for baseline recordings and 2 – 4 more were 
made following acute infusion of NIC. Putative pyramidal cells were identified as those with 
spikes in a biphasic waveform, a spike width > 2.0 ms, and a firing rate < 2 Hz. 
Histology. At the conclusion of each electrophysiological recording, rats were sacrificed 
with an overdose of chloral hydrate (addl. 400 mg/kg, i.p.). The recording site was marked by an 
electrophoretic injection of Chicago Sky blue (- 20 A for 20-30 minutes). Animals were then 
decapitated and brains were fixed in 8% paraformaldehyde in 0.2 M PBS and cryoprotected in 
25% sucrose in 0.2 M PBS. Sixty-micrometer sections were taken throughout VTA or vHipp and 
stained with 95% Neutral Red and 5% Cresyl Violet in order to verify electrode placement. Due 
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to laboratory closures caused by the COVID-19 pandemic, brains from a subset of animals in the 
Acute NIC vHipp recording experiment could not be processed.   
Data analysis. Data collected during electrophysiological recordings were analyzed using 
LabChart and NeuroExplorer software to determine firing rate and, in DA neuron recordings, 
percentage of spikes occurring in bursts. DA population activity, defined as the average number 
of spontaneously active neurons encountered per electrode track, was calculated for each animal 
at baseline and after NIC infusion. Values are reported as mean  SEM unless otherwise stated. 
Statistical analyses were performed using GraphPad Prism 8. Analyses of firing rate, bursting, and 
population activity within each experiment were conducted using a two-way mixed ANOVA, with 
Group (MAM vs. CTL) as between-subjects factors and Drug (Baseline vs. Post-NIC) as within-
subjects factors when possible, followed by post-hoc tests (α =0.05; reported p values are adjusted 
for multiple comparisons using Bonferroni correction). 
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4.3 RESULTS 
Acute NIC treatment normalizes DA population activity in MAM animals. Analysis of 
population activity in drug-naïve MAM (n = 7 rats; 3 M/4 F) and CTL animals (n = 5 rats; 4 M/1 
F) at baseline and after NIC treatment revealed a significant effect of Drug (F1,10 = 9.0, p < 0.05) 
and a significant Group x Drug interaction (F1,10 = 4.8, p = 0.052). Post-hoc tests indicated that 
MAM animals showed significantly elevated DA population activity at baseline (1.01  0.01 
cells/track) relative to CTL animals (0.66  0.07 cells/track, p < 0.05). However, as hypothesized, 
population activity in MAM animals was significantly reduced after NIC administration (0.44  
0.15 cells/track, p < 0.01; Figure 9A). There were no significant effects of Group or Drug on 
average firing rate or on bursting (Figure 9B,C.)  
 
 
 
 
 72 
 
Figure 9: Acute NIC normalizes elevated DA population activity in MAM animals 
Electrophysiological data collected from spontaneously active neurons in VTA. (A) At Baseline, population 
activity of VTA DA neurons was significantly higher in MAM than CTL animals. Acute systemic NIC 
infusion normalized this elevated activity, significantly lowering the number of cells encountered per track 
relative to Baseline. (B, C) MAM and CTL animals did not differ in mean firing rate or percentage of spikes 
in burst at Baseline or Post-NIC.  CTL rats, blue circles/bars; MAM rats, red squares/bars; * p < 0.05; **p 
< 0.01; Bar labels indicate number of cells analyzed (number of animals). 
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DA population activity is comparable in MAM and CTL animals after chronic NIC. 
MAM and CTL rats (n = 6 per group; 4 M/2 F) were injected with NIC (0.3 mg/kg, s.c.) daily for 
at least 12 days. When measured 24 hours after their last injection (Baseline) and then after a single 
infusion of NIC (Post-NIC), there was no effect of Drug (p = 0.18) or Group (p = 0.29) and no 
Drug x Group interaction (p = 0.56) on VTA DA population activity in MAM and CTL rats (Figure 
10A). Similarly, there were no effects on average firing rate or on bursting in these animals (Figure 
10B,C).  
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Figure 10: VTA DA neuron activity is comparable in CTL and MAM animals after chronic NIC 
Electrophysiological data collected from spontaneously active neurons in VTA. (A) CTL and MAM 
animals chronically treated with NIC demonstrated comparable VTA DA population activity at a 24 h 
Abstinent baseline and after acute NIC infusion. (B, C) MAM and CTL animals did not differ in mean 
firing rate or percentage of spikes in burst at Baseline or Post-NIC. CTL rats, blue circles/bars; MAM rats, 
red squares/bars; Bar labels indicate number of cells analyzed (number of animals). 
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Acute NIC significantly reduces elevated vHipp firing rates in MAM animals. Analysis of 
average firing rates of putative pyramidal cells in vHipp of MAM (n = 8 rats; 5 M/3 F) and CTL 
(n = 8 rats; 5 M/3 F) animals revealed a significant effect of Group (F1,28 = 5.96, p < 0.05, Figure 
11A) but no effect of Drug (p = 0.27) and no Group x Drug interaction (p = 0.17). A Student’s t-
test of average firing rates in drug-naïve animals supported the a priori hypothesis that firing 
rates in MAM animals (1.23 ± 0.1 Hz) were significantly higher than those in CTL animals (0.84 
± 0.11 Hz) measured at Baseline (t14 = 2.69, p < 0.05). Additionally, average Post-NIC firing 
rates (0.98 ± 0.11 Hz) in MAM animals were significantly lower than those measured at Baseline 
(t7 = 2.45, p < 0.05) and not significantly different from Baseline firing rates in CTL animals (p = 
0.38). 
Average vHipp neuronal firing rates do not differ in MAM and CTL animals after chronic 
NIC treatment. As in the DA recording experiment, MAM (n = 7 rats; 4 M/3 F) and CTL rats (n 
= 7 rats; 3 M/4 F) were injected with NIC (0.3 mg/kg, s.c.) daily for at least 12 days. A two-
way ANOVA of averaged neuronal firing rates in each animal revealed no significant effects of 
Group (p = 0.53) or Drug (p = 0.43) and no Group x Drug interaction (p = 0.27; Figure 
11B). As hypothesized, mean firing rates of cells recorded from vHipp in chronically treated 
MAM (0.88 ± 0.2 Hz; n = 17 cells/7 animals) and CTL animals (0.82 ± 0.08 Hz; n = 23 cells/7 
animals) did not differ after acute NIC infusion (t11 = 0.31, p = 0.76).  
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Figure 11: Acute and chronic NIC normalizes elevated firing rates of vHipp neurons 
(A) Mean firing rates of spontaneously active neurons encountered in vHipp were significantly higher in 
NIC-naïve MAM animals than CTL at Baseline. However, acute systemic infusion of NIC significantly 
decreased mean firing rates in MAM animals, normalizing this elevation. (B) vHipp neuronal firing rates 
measured in chronically NIC-treated MAM and CTL animals did not differ when measured at a 24 h 
Abstinent baseline or after acute NIC infusion. CTL rats, blue bars; MAM rats, red bars; * p < 0.05; Bar 
labels indicate number of cells analyzed (number of animals). 
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4.4 DISCUSSION 
 
These experiments aimed to examine the effects of acute and chronic NIC on 
neurophysiological perturbations in the MAM rodent model of SCZ. High rates of smoking among 
SCZ patients are often hypothesized to be a form of “self-medication”, driven by NIC-induced 
relief of some symptoms of the illness. While evidence does suggest some mixed positive effects 
of NIC on certain cognitive and behavioral symptoms, little is known about the impact of NIC 
intake on neurophysiological mechanisms underlying these symptoms (Valentine and Sofuoglu 
2018). Ventral hippocampal hyperactivity driving elevated VTA DA neuron activity is a 
mechanistic hallmark of the MAM model, and the disruptions in both VTA and vHipp activity in 
model animals parallel those observed in many neuroimaging studies of patients (Modinos et al. 
2015). Based on prior evidence that NIC can improve some behavioral deficits and that systemic 
7 nAChR agonists can normalize elevated DA population activity in MAM animals via action in 
vHipp, our experiments sought to explore a potential link between these observations (Neves and 
Grace 2018). We conducted in vivo electrophysiological recordings of VTA DA and vHipp 
pyramidal cell activity to test the hypothesis that acute NIC can normalize hyperactivity in both 
regions. Our findings demonstrate that a single, behaviorally-relevant systemic dose of NIC 
normalizes elevated VTA DA population activity observed in MAM animals and that this effect 
persists after chronic NIC treatment, even in acute abstinence. Acute NIC administration also 
significantly reduced elevated vHipp neuron firing rates observed in MAM animals, and 
differences between MAM and CTL animals remain mitigated after chronic NIC treatment. These 
results confirm the hypothesis that NIC can mitigate DA population hyperactivity in the MAM 
model and may support a direct mechanism via reduction of vHipp hyperactivity.  
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These experiments aimed to model the neurophysiological impact of NIC administration 
in smoking versus nonsmoking patients captured in human studies by examining the effects of 
acute NIC doses at both a drug-naïve baseline and at a 24-hour abstinent baseline in chronically 
treated animals. This distinction is particularly critical, as findings on the cognitive and behavioral 
effects of NIC in SCZ patients can vary widely by smoking status. Indeed, some cognitive deficits 
in SCZ smokers may be further exacerbated by acute NIC withdrawal, while positive effects of 
NIC on performance may be most robust in nonsmokers (AhnAllen et al. 2008; Jubelt et al. 2008). 
Prior studies in the MAM model have demonstrated positive effects of acute NIC and nAChR 
agonists on sensory gating deficits and DA hyperactivity, but our study is the first to examine 
comprehensively the effects of both acute and chronic NIC admin on VTA and vHipp neuronal 
activity in this model (Kohlhaas et al. 2015; Neves and Grace 2018). Because drug-naïve and 
chronically-treated animals were studied in separate experiments at separate times, we cannot 
make direct statistical comparisons between the results of these experiments. It is thus challenging 
to interpret at face value the finding that DA population activity measured at a 24-hr Abstinent 
Baseline in chronically-treated CTL animals (0.88  0.12 cells/track) appears to be higher than at 
Baseline in drug-naïve CTL animals (0.66  0.07 cells/track) and more similar to drug-naïve MAM 
animals (1.01  0.10 cells/track) at Baseline. This could suggest that chronic NIC treatment 
elevates DA population activity observed in acute abstinence in CTL animals. Our baseline 
findings of DA population activity in both MAM and CTL animals are somewhat lower than prior 
published observations, though we have replicated the relative difference between these groups 
observed in other studies (Lodge and Grace 2007). Our results support further study of acute and 
chronic effects of NIC on neurophysiological disruptions in MAM animals in order to make more 
direct comparisons.  
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There are several key limitations to our study design that may be considered in the 
interpretation of our findings. We elected to use experimenter-administered rather than self-
administered NIC in our study in order to precisely control the timing and quantity of NIC received 
by all animals. While the dose selected (0.3 mg/kg, s.c.) for chronic NIC treatment is a moderate 
NIC dose relevant to human consumption, intravenous NIC self-administration in Chronic NIC 
experiments would be more representative of the pharmacokinetics of smoking. Additionally, the 
nature of the electrophysiological recordings performed in these experiments precluded us from 
directly examining how changes in neuronal activity after NIC administration may impact 
behavioral deficits in the MAM model. Future experiments utilizing recording techniques in 
awake, behaving animals would critically inform the relationship between normalization of 
neuronal dysfunction and resulting behavioral outcomes. An additional point of consideration of 
these data is that our experiments pooled male and female subjects in each group but were not 
statistically powered to detect sex differences as a variable of interest. We did not anticipate sex 
differences in MAM rats, as prior studies of this question have demonstrated consistent behavioral 
impairments and neurophysiological disruptions between male and female rats, including 
alterations in hippocampal spike timing and PV interneuron expression (Perez et al. 2019; Hernan 
et al. 2018). Limited study of GD17 MAM administration in mice has indicated some sex 
differences in the resulting phenotype, though it is unclear if these are distinct to the species and 
if they may interact with effects of NIC (Chalkiadaki et al. 2019).  
To date, no published study has examined the effects of NIC on neurophysiological 
dysfunction observed in the MAM model. However, a 2018 study by Neves and Grace 
demonstrating that 7 nAChR agonist administration can normalize elevated VTA DA population 
activity in MAM animals via action in vHipp led us to hypothesize that administration of NIC may 
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produce similar results (Neves and Grace 2018). NIC exerts effects on multiple neurotransmitter 
systems by binding with nAChRs expressed on both excitatory and inhibitory cells, producing 
modulatory effects throughout the brain that vary across states of nAChR activation and 
desensitization (Picciotto and Mineur 2014; Picciotto et al. 2008). Co-labeling experiments have 
indicated that both 42 and 7 nAChRs are highly expressed on parvalbumin-positive (PV) 
inhibitory interneurons in the hippocampus, and decreased expression of PV is a well-established 
finding in studies of post-mortem tissue in SCZ (Freedman et al. 2000). In addition, reductions in 
functional 7 nAChRs are also observed in multiple regions of post-mortem SCZ brains, including 
thalamus, frontal cortex, and hippocampus (Leonard et al. 2002; Freedman et al. 1995). 
Unpublished [125I]-labeled -bungarotoxin autoradiography data from our lab suggest that 
expression of functional 7 nAChRs is also reduced in the vHipp of male MAM animals 
(Appendix A). Together, these findings may suggest a mechanism by which activation of both 
high-affinity 42 and low-affinity 7 nAChRs by high NIC concentrations may serve to 
potentiate activation of these regions of reduced expression and thus mitigate imbalances in 
excitation and inhibition that produce behavioral and neurophysiological deficits.  
Here, particularly, we proposed that activation of nAChRs on inhibitory interneurons of 
vHipp may serve to normalize increased activity of vHipp pyramidal cells and, in turn, restore 
proper inhibition of the NAcc-ventral pallidum (VP) GABAergic input, which normalizes the 
increased DA population activity observed in VTA. We thus hypothesized that we would observe 
NIC-induced decreases in firing rate of putative pyramidal cells and of VTA DA population 
activity. While we did find that both acute and chronic systemic NIC administration normalized 
hyperactivity in both vHipp and VTA in MAM animals as hypothesized, our results cannot confirm 
that these effects occur via direct action of NIC on nAChRs in vHipp and its resulting drive to 
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VTA inputs. The use of systemic NIC in these experiments was justified by its relevance to NIC 
intake in human smokers but does limit the potential to draw mechanistic conclusions from our 
findings. Additionally, higher-affinity non-7 nAChRs are found throughout hippocampus, 
maintaining the possibility that the effects of NIC observed in our experiments are not due to action 
on 7 nAChRs in vHipp (Yakel 2012). However, results of prior clinical and preclinical studies 
illustrating the particular role of vHipp 7 nAChRs in SCZ-related neuronal dysfunction converge 
with our finding that the effects of NIC on VTA and vHipp neuronal activity were specific to 
MAM animals and not observed in CTL rats (Neves and Grace 2018; Kohlhaas et al. 2015; 
Freedman et al. 2000). This suggests a mechanism that is particular to the pathophysiology of 
MAM. Further experiments employing regional, nAChR subtype-specific antagonism could better 
elucidate the precise mechanism by which systemic NIC reduces both vHipp and VTA DA 
hyperactivity in MAM animals. Importantly, the potential for normalization of VTA activity via 
vHipp has implications for effects on other projection regions, providing an additional potential 
mechanism by which NIC may modulate behavioral deficits in SCZ. Further studies are necessary 
to better clarify the potential mechanistic link between NIC effects on neuronal activity in vHipp 
and VTA and how these may change over the course of repeated administrations.  
A wide body of research indicates a promising role for NIC and nicotinic agonist drugs in 
mitigating cognitive and sensory gating dysfunction in SCZ. Elevated rates of smoking among 
SCZ patients are often attributed to a “self-medication hypothesis”, proposing that NIC delivered 
through cigarettes reduces some cognitive or negative symptoms of the disease (Kumari and 
Postma 2005). Developing an understanding of this relationship and the role it may play in tobacco 
use is critical to reducing persistent tobacco-related health disparities among individuals with SCZ. 
Additionally, the effects of NIC as well as acute abstinence from NIC are important to consider in 
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future NIC reduction policy, as there may be disparate effects of lower NIC product standards on 
quality of life and function in patients (Khantzian 2016). Based on findings that 7 nAChR 
agonists may normalize elevated DA population activity in the MAM model via action in vHipp, 
our experiments sought to explore the potential relationship between this neurophysiological 
mechanism and the established behavioral effects of NIC. Our experiments confirmed that, like 
7-specific agonists, systemic NIC administration can normalize elevated VTA DA population 
activity observed in MAM animals, and that this effect persists in chronically-treated animals. 
Additionally, we demonstrated that both acute and chronic NIC administration can also normalize 
hyperactivity in vHipp, suggesting a potential means by which a reduction of vHipp output may 
in turn reduce VTA DA population activity. Future work can build upon our findings through more 
direct mechanistic study of vHipp activity and resulting effects on VTA DA output and through 
experimental connection of these neurophysiological findings with relevant behavioral outputs. 
Our findings nonetheless are a valuable contribution to the growing understanding of the 
neurophysiological and behavioral effects of NIC in SCZ developed through studies in animal 
models of the disease.  
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5.0 GENERAL DISCUSSION 
5.1 SUMMARY OF FINDINGS 
The studies summarized in this document aimed to assess two prevailing hypotheses 
behind high rates of smoking observed in people with SCZ using the MAM rodent model, a well-
validated animal model of key neurophysiological and behavioral elements of the disease.  
In Chapter 2, we described a series of experiments comparing the primary reinforcing and 
reinforcement-enhancing effects of NIC in MAM and CTL animals using NIC self-administration. 
Ultimately, we sought to evaluate the hypothesis that SCZ pathophysiology, particularly as it 
relates to DA hyperactivity, confers increased NIC reward and leads to higher rates of smoking in 
SCZ. Our findings demonstrated that self-administration of NIC, across a range of doses or paired 
with other reinforcers, is not increased in the MAM model of SCZ (Weeks et al. 2020). These 
results failed to support a “reinforcement hypothesis” behind increased rates of smoking in SCZ. 
The experiments in Chapters 3 & 4 then assessed the effects of both acute and chronic 
NIC on several behavioral measures of cognitive dysfunction and on neurophysiological 
disruptions observed in the MAM model. We presented findings that NIC, administered both 
acutely and chronically, can normalize auditory PPI and NOR in MAM animals. These results 
illustrated that NIC can improve certain SCZ-relevant cognitive impairments and sensory gating 
deficits modeled by gestational MAM administration. Additionally, the findings presented in 
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Chapter 4 suggested that NIC administration normalizes neurophysiological disruptions as well. 
Both acute and chronic NIC reduced neuronal hyperactivity in VTA and in vHipp to levels 
comparable to CTL animals. Taken together, these findings lent support to the other prevailing 
theory behind increased smoking, a “self-medication” hypothesis. The finding that both acute and 
chronic NIC administration normalized SCZ-relevant behavioral and neurophysiological 
dysfunction in the MAM rodent model of SCZ suggests the potential for a mechanism by which 
NIC intake could improve symptoms in smokers.  
5.2 RELEVANCE TO THEORIES EXPLAINING INCREASED SMOKING IN 
SCHIZOPHRENIA 
5.2.1 Evaluating the “reinforcement hypothesis”. 
The “reinforcement hypothesis” of increased smoking in SCZ posits that high rates of 
heavy smoking among individuals can be attributed to altered reinforcement or reward dysfunction 
in the disease. This wider theory, however, can be approached from several angles. One 
interpretation is that NIC reinforcement is greater in SCZ smokers than in controls, likely as a 
result of higher NIC-stimulated mesolimbic DA release and an increased vulnerability to addiction 
(Chambers et al. 2001). Indeed, some behavioral evidence does support this idea of increased NIC 
reinforcement. Smokers with SCZ demonstrate a distinctly heavy pattern of smoking, consuming 
more cigarettes per day, taking more puffs per cigarette, and reporting higher levels of craving 
than nonpsychiatric control smokers (Tidey et al. 2005). Additionally, in behavioral economic 
analyses, SCZ smokers exhibited a higher intensity of cigarette demand than control smokers 
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(MacKillop and Tidey 2011). While SCZ smokers’ demand for cigarettes was sensitive to 
hypothetical changes in cigarette price, this group reported significantly higher demand for 
cigarettes at hypothetical low prices and higher rates of consumption during an ad libitum smoking 
task than control smokers, suggesting some differences in smoking reinforcement. Smokers 
assessed on decisional balance indices to evaluate the degree to which they perceive benefits versus 
disadvantages of smoking also vary by psychiatric status. Interestingly, control smokers reported 
a near-balanced perception of pros and cons of smoking, while both depressed and SCZ smokers 
reported significantly greater benefits of smoking, even after controlling for nicotine dependence 
severity (Spring et al. 2003). This could support the theory that smoking is more reinforcing in 
SCZ smokers than in controls, but the finding that depressed and SCZ smokers reported similar 
perceptions of smoking-related benefits would suggest that this difference in reinforcement is not 
unique to SCZ pathophysiology. The experiments described in Chapter 2 sought to directly 
compare NIC reward in CTL and MAM animals using intravenous self-administration, the gold 
standard in studies of NIC reinforcement (Ator and Griffiths 2003). Though elevated DA 
population activity is one of the primary physiological hallmarks of the MAM model, and that 
altered DA activity is thought to underlie increased sensitivity to NIC reward, no prior experiments 
had assessed NIC self-administration in this model. We found that self-administration of NIC, 
alone or in combination with a reinforcing VS, was not increased in MAM animals (Chapter 2). 
This suggests that SCZ-related DA pathophysiology modeled by gestational MAM administration 
does not produce increased NIC reinforcement relative to controls.  
However, the reinforcement hypothesis could also imply that NIC is more rewarding to 
SCZ individuals than other rewards, which are more weakly reinforcing than in controls, leading 
to higher rates of smoking. SCZ smokers assessed on a hypothetical choice task were more likely 
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than control smokers to select cigarettes over other rewards, such as eating a favorite candy or 
seeing a movie (Spring et al. 2003). Importantly, this difference was also observed in depressed 
patients, suggesting a behavioral mechanism not necessarily exclusive to SCZ symptomology. The 
results of experiments from Chapter 2 lend some support to the hypothesis that rewarding effects 
of NIC are elevated relative to other reinforcers in SCZ. MAM animals self-administered fewer 
infusions paired with VS presentations than CTL animals at all doses of NIC besides 100 µg/kg, a 
relatively high dose. MAM animals’ lower responding for the reinforcing VS than CTL animals 
in absence of NIC (0 µg/kg) and reduced response breakpoints for sucrose rewards could suggest 
reduced responsivity to non-NIC rewards in this group. The finding that self-administration of NIC 
alone was comparable between MAM and CTL animals across a range of doses in this study would 
in turn suggest that NIC reinforcement in MAM animals, while not greater than in CTL, is greater 
than reinforcement from non-NIC rewards.  
A further possible interpretation of the reinforcement hypothesis is that this difference in 
valuation of NIC versus non-NIC rewards is related to symptoms of anhedonia in SCZ. Indeed, 
increased levels of negative symptoms in SCZ, such as flattened affect and anhedonia, have been 
associated with higher rates of smoking and less success in smoking cessation (Ameringer and 
Leventhal 2010; Dutra et al. 2012). Baseline NIC withdrawal severity and non-deprived urge to 
smoke were also positively correlated with blunted affect and anhedonia among SCZ smokers, but 
not controls (AhnAllen et al. 2012). Importantly, work studying the nature of anhedonia symptoms 
in SCZ has suggested that deficits are specific to anticipatory pleasure, and that experiences of 
consummatory pleasure seem to be comparable in SCZ patients and controls (Gard et al. 2007). 
Higher reports of craving and urge to smoke in SCZ smokers measured both in non-deprived and 
acutely abstinent conditions (Tidey et al. 2014) are thus interesting, as they reflect a more intense 
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anticipation of smoking without necessarily relating to the experience of smoking itself. This 
further suggests that, in SCZ smokers, NIC may be uniquely reinforcing relative to other rewards 
and that this may be related to symptoms of anhedonia. A study of reward-based learning in SCZ 
and control smokers found that, while both groups were comparable in patterns of reward-based 
learning, decreased responsiveness to rewards was associated with higher dependence in SCZ 
smokers only (AhnAllen et al. 2012). This finding could imply that SCZ smokers with reduced 
hedonic function or capacity are more reliant on NIC for normalization of reward system 
functioning, and thus more dependent on NIC. The reinforcement-enhancing effects of NIC could 
contribute to this relationship by modulating responses to non-NIC rewards (Rupprecht et al. 
2015), essentially normalizing blunted reward responses in SCZ. However, in briefly NIC-
deprived, nonpsychiatric control smokers, higher reports of cigarette craving have been associated 
with lower responsivity to monetary rewards (Peechatka et al. 2015). In SCZ patients experiencing 
symptoms of anhedonia, then, NIC dependence and craving could perpetuate a relationship 
between smoking, NIC reinforcement, and reward responsivity by further reducing responses to 
non-NIC rewards. Taken together, the findings described above suggest that a “reinforcement 
hypothesis” may not necessarily imply that individuals with SCZ are more likely to smoke because 
they experience greater NIC reward than controls, and that NIC reinforcement in SCZ may be 
associated with symptom severity. 
5.2.2 Cognitive and neurophysiological effects of nicotine as evidence for “self-medication”. 
The second popular theory underlying increased smoking among SCZ patients is a “self-
medication hypothesis”. This suggests that individuals with SCZ smoke as a means of managing 
or relieving cognitive and/or negative symptoms of the disease with NIC (Kumari and Postma 
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2005). As reviewed in Chapter 3, numerous studies of subjects with SCZ have demonstrated 
improvements in sensory gating deficits and in impaired cognitive domains such as attention and 
working memory after administration of NIC. For example, SCZ smokers administered NIC nasal 
spray or allowed to smoke prior to testing demonstrate increased levels of auditory PPI relative to 
both SCZ nonsmokers and briefly deprived smokers (Hong et al. 2008; Kumari et al. 2001). 
Additionally, when allowed to smoke ad libitum, SCZ smokers exhibit increased PPI to levels 
comparable to control smokers (Woznica et al. 2009). NIC-induced improvements in cognitive 
domains have also been reported, suggesting further motivation for self-medication. For example, 
administration of a transdermal NIC patch significantly improved attentional performance on the 
Continuous Performance Test in both SCZ and control nonsmokers, and improved impulsive 
responding to a greater degree in SCZ subjects (R. S. Barr et al. 2008). The findings of our 
experiments detailed in Chapters 3 & 4 support elements of the self-medication hypothesis by 
providing both behavioral and neurophysiological evidence of NIC-induced improvements in a 
model capturing certain key system dysfunctions in SCZ. We found that acute administration of 
NIC mitigated PPI deficits and impairments in the NOR task in MAM animals and normalized 
increased activity in VTA and vHipp in these animals. Importantly, we also found that MAM and 
CTL animals did not differ in behavioral performance after chronic treatment with NIC. This was 
a critical measure, as some lines of evidence suggest that NIC-induced improvements in smoking 
patients are merely a result of relief from withdrawal, or that NIC does not improve symptom 
measures in smokers. For example, an assessment in multiple indices of cognitive function before 
and after the use of NIC gum demonstrated improved measures of attentional function only in 
nonsmokers, with no benefit in smokers (Harris et al. 2004). Another study of smokers found that 
overnight abstinence exacerbated deficits in spatial working memory and attention in SCZ 
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smokers, and that smoking resumption increased performance in these areas (Sacco et al. 2005). 
Our experiments found that chronically NIC-treated animals, when measured at a 24-hr abstinence 
period, did not differ in behavioral or neurophysiological measures. While the study design 
precludes us from directly comparing these measurements to those obtained in the acute 
administration experiments, our findings suggest that this does not reflect a decline in CTL 
animals’ performance and function, but rather a persistent normalization of these indices in MAM 
animals.  
Our studies, however, cannot provide insight into if or how the normalizing effects of NIC 
on behavioral and neurophysiological dysfunction in SCZ may motivate smoking as a means of 
“self-medication”. Few studies assess self-reported motivators for smoking among SCZ patients, 
but the most commonly cited reasons for smoking in these reports are calming or sedative effects 
of smoking, improvement of negative symptoms, and relief of craving (Gurpegui et al. 2007; 
Forchuk et al. 2002). It is possible, then, that these reported motivators for smoking, in combination 
with modest improvements in sensory gating impairments and cognitive dysfunction, produce a 
general state of “feeling better” that may drive smoking among SCZ individuals. That is, perhaps 
some of the effects of NIC on SCZ symptomology observed in experimental measures are not 
clearly discernible in daily life, and that self-medication through smoking reflects a general means 
of “feeling better” without necessarily targeting specific cognitive deficits. 
5.2.3 A potential merging of the reinforcement and self-medication hypotheses. 
Despite their considerable differences, the two most prominent hypotheses explaining 
increased smoking in SCZ are not mutually exclusive, and could, in fact, come together into a 
broader hypothesis encompassing elements of both theories. Based on the evidence described 
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above, it is possible that heavy smoking in SCZ is driven by uniquely reinforcing effects, in that 
“feeling better” after smoking provides a form of negative reinforcement. This general 
improvement of some symptomology could perpetuate smoking behavior as a means of relief from 
unpleasant states related to SCZ, even if patients do not consciously consider this action as a means 
of “self-medication”. Additionally, the potential effects of NIC intake on negative symptom 
severity in SCZ smokers could impact cognitive symptoms as well. Negative symptoms affecting 
reward, such as anhedonia and avolition, have an overlapping impact on overall cognitive function, 
as motivation, effort allocation, and value representation are processes necessary to many 
cognitive demands (Robison et al. 2020). A study of SCZ smokers and nonsmokers demonstrated 
a correlation of performance on the Iowa Gambling Task (IGT), a measure of reward-based 
learning, and the Wisconsin Card-Sorting Task, a test of cognitive flexibility. This finding could 
reflect associated levels of function in reward processing and executive functioning (Yip et al. 
2009). Negative reinforcement through relief of withdrawal symptoms is also considered a 
significant motivator of continued smoking behavior in the general population (Robinson et al. 
2012). While this could be an important additional factor in driving persistent smoking in SCZ 
smokers as well, as patients report more severe withdrawal symptoms after 72-hr abstinence than 
control smokers (Tidey et al. 2014), it does not preclude the possibility of reinforcement related to 
cognitive and affective states as a motivator of NIC intake.  
Our studies indicate that acute NIC administration can improve cognitive impairments and 
sensory gating deficits and normalize abnormal neuronal activity in the MAM rodent model of 
SCZ. Our findings also suggest that these effects are lasting and persistent with repeated 
treatments, as animals treated chronically with NIC demonstrate continued normalization of these 
measures. Importantly, these results do not illustrate further impairment of cognitive function after 
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24-hr abstinence in chronically treated animals. When measured at this briefly abstinent baseline, 
MAM and CTL animals were comparable in behavioral and neurophysiological measures, 
suggesting that overnight NIC abstinence may not produce an exacerbation of SCZ-related 
dysfunction and that NIC may have sustained positive effects on behavioral and 
neurophysiological disruptions in this model. Overall, the results of our experiments provide 
support for some aspects of both the reinforcement and self-medication hypotheses. While NIC is 
not more reinforcing in MAM animals than controls, our findings suggest that NIC may be 
uniquely reinforcing relative to other rewards in this model. Furthermore, the findings described 
in Chapters 3 & 4 indicate that both acute and chronic NIC administration can normalize SCZ-
related behavioral and neurophysiological dysfunction modeled by gestational MAM 
administration. Taken together, these results could provide evidence for a merged hypothesis, 
where the effects of NIC on reward-related deficits as well as cognitive functioning and underlying 
neurophysiological processes may reinforce continued smoking behavior in SCZ.  
5.3 CONTRIBUTION TO PROPOSED MECHANISM OF NICOTINE’S EFFECTS IN 
SCHIZOPHRENIA 
Nicotinic receptors have long been of interest in the study of SCZ pathophysiology and 
development of potential therapeutics. Multiple lines of evidence suggest that the 7 nAChR 
subtype is of particular relevance to the disease. Briefly, 7 nAChRs are homomeric receptors 
with rapid desensitization kinetics and high permeability to Na+, K+, and Ca2+. This high Ca2+ 
permeability is critical to the receptor’s effects in depolarizing postsynaptic cells, regulating 
neurotransmitter release, and initiating downstream cellular processes. These receptors have a 
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lower affinity for NIC than most other nAChRs and thus require high concentrations of the drug, 
such as those achieved through patterns of intense, heavy smoking observed in SCZ smokers, to 
be activated (Corradi and Bouzat 2016). 7 nAChRs are particularly abundant in regions 
implicated in memory and cognitive function, including hippocampus and cortex, and play a 
critical role in modulating synaptic transmission throughout the brain (Lendvai et al. 2013). 
Importantly, post-mortem studies of patient tissue have revealed a significant reduction in binding 
of [125I]-labeled -bungarotoxin in the hippocampus, frontal cortex, and thalamus of SCZ brains, 
indicating a reduction in 7 subunit expression in these regions (Guan et al. 1999; Freedman et al. 
1995; Court et al. 1999). Our preliminary evidence from [125I]-bungarotoxin autoradiography 
suggests that a decrease in 7 nAChR expression is also observed in the vHipp of male MAM 
animals (Appendix A). Genetic evidence associates these abnormalities in 7 nAChR function 
with wider implications for SCZ prevalence, symptom severity, and smoking behavior. 
Abnormalities in CHRNA7, the gene encoding the 7 nAChR subunit, are reliably linked to the 
P50 sensory gating deficit in patients and first-degree relatives, and further studies have 
demonstrated the gene’s association with PPI, visual information processing, and episodic memory 
dysfunction (Bakanidze et al. 2013; Freedman 2014). CHRNA7 variants associated with smoking 
prevalence, both overall and in SCZ patients in particular, have also been identified (Stephens et 
al. 2012; De Luca et al. 2004). 
 Evidence also suggests that expression and function of 42 nAChRs may be altered in 
SCZ, as autoradiographic analyses have demonstrated decreased levels of these receptors in 
hippocampus, striatum, and cortex in patient tissue relative to controls (Ripoll et al. 2004). In 
addition to their role in modulating neurotransmitter release throughout the brain, similarly to 7 
nAChRs, these receptors are also particularly implicated in the reinforcing effects of NIC. 42 
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nAChRs are prominently expressed on presynaptic terminals of DA neurons, and nearly 100% of 
neurons in VTA express mRNA for the 4 and 2 subunit (Klink et al. 2001). Systemic or intra-
VTA administration of DHE, an antagonist selective for 4- and 2-containing nAChRs, has 
been demonstrated to decrease NIC self-administration and minimize NIC-induced lowering of 
intracranial self-stimulation thresholds in rats (Fowler et al. 2008), suggesting that stimulation of 
42 nAChRs is critical to the effects of NIC on brain reward systems. Additionally, while 
significant upregulation of high-affinity nAChRs is consistently observed in control smokers due 
to chronic NIC exposure, this process may be altered in smokers with SCZ. A study of postmortem 
tissue from SCZ subjects and nonpsychiatric controls demonstrated that binding of the high affinity 
receptor ligands [3H]-epibatidine and [3H]-nicotine in cortex, hippocampus, and caudate increased 
as a function of smoking status in both groups, though to a significantly lesser degree in samples 
from SCZ patients (Breese et al. 2000). These findings suggest that decreased levels of 42 
nAChR expression, both in NIC-naïve and smoking SCZ subjects, could contribute to differences 
in responses to stimulation by NIC as well as endogenous ACh.  
Despite the wealth of research into the potential mechanistic role of nAChR stimulation in SCZ 
and its relationship to smoking, this relationship remains largely unexplored in the MAM model. 
Recent work by Neves & Grace (2018) demonstrated that administration of an 7 nAChR agonist, 
either systemically or directly into the vHipp, normalized the elevated VTA DA population activity 
observed in MAM animals and had no effect on CTL animals. This finding suggests a critical role 
for 7 nAChR activation in modulating abnormal vHipp drive to the GABAergic NAc-VP input 
to VTA, and that this effect may be unique to the altered hippocampal-striatal activity observed in 
MAM animals (Lodge and Grace 2007). The experiments described in Chapter 4 confirmed a role 
for nicotinic stimulation in modulating vHipp output as well as VTA DA population activity. We 
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demonstrated that systemic NIC administration can normalize the elevated firing rate observed in 
putative pyramidal neurons of the vHipp as well as elevated VTA DA population activity in MAM 
animals. However, because NIC broadly activates nAChRs, these results do not provide insight 
into specific nAChR subtypes responsible for these actions. These and other findings suggest roles 
of multiple nAChR subtypes, including high-affinity subtypes such as 42 nAChRs, in 
modulating SCZ pathophysiology modeled in MAM animals. Indeed, while 7 nAChRs are 
critical in these mechanisms, numerous receptor subtypes are at play in both neurophysiology and 
related behavioral output. For example, NIC administration improves learning in WT but not 7 
null mice, but 7 agonists do not improve learning (Milienne-Petiot et al. 2018). This finding could 
illustrate that 7 nAChR stimulation is likely necessary, but not sufficient, for normalization of 
cognitive deficits. 
As mentioned previously, reinforcement-based explanations for increased smoking in SCZ 
have been largely associated with alterations in the mesolimbic reward system. Endogenous 
cholinergic inputs from pedunculopontine tegmentum (PPTg) to VTA are critical in modulating 
DA neuronal activity, as nAChRs are expressed not only in VTA DA cells, but on glutamatergic 
and GABAergic cells of the VTA as well (Mansvelder et al. 2002). As previously discussed, high-
affinity 2 subunit-containing receptors in this region are known to be crucial in the rewarding 
effects of NIC, though 7 nAChRs are also expressed in VTA. Cholinergic inputs from PPTg, as 
well as glutamatergic afferents also regulated by nAChR activity, are critical in transitioning DA 
neurons from tonic to burst firing patterns (Leslie et al. 2013). In the state of elevated DA 
population activity observed in the MAM model, then, one might expect a greater NIC-induced 
excitation in VTA DA neurons, as more spontaneously active neurons would be available to 
respond (Lodge and Grace 2009). However, the results of experiments in Chapter 4 were 
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relatively surprising in this respect, as acute NIC administration did not increase bursting or overall 
firing rates of spontaneously active VTA DA neurons in MAM or CTL animals. While it is 
possible that a transient initial increase in activity after NIC administration was briefly observed 
and then normalized due to receptor desensitization, 642-containing nAChRs in VTA remain 
persistently activated for minutes after desensitization (Leslie et al. 2013) This finding could 
suggest that action of NIC on nAChRs in other regions may have prevented this increase.  
Afferents from vHipp are additional critical sites of nicotinic modulation that can impact 
activity throughout the brain. Evidence from the MAM model suggests that increased activity of 
vHipp excitatory projections to the NAcc-VP circuit disinhibits VTA DA cells and produces the 
elevated DA population activity thought to contribute to positive-like symptoms in these animals 
(Lodge and Grace 2007). Selective loss of  a specific population of inhibitory interneurons 
expressing the calcium-binding protein parvalbumin (PV) appears to be key in this vHipp 
hyperactivity, as lentiviral knockdown of PV expression in vHipp produces increases in vHipp 
firing rates comparable to those observed in MAM animals (Boley et al. 2014). Importantly, 
decreased PV expression is consistently observed in PFC and vHipp of postmortem SCZ tissue 
(Beasley and Reynolds 1997; Zhang and Reynolds 2002), a finding which is replicated in the 
MAM model and is likely responsible for impaired functional coupling between these regions 
during cognitively demanding tasks (Lodge et al. 2009). Because afferents of PFC and 
hippocampus project to diverse regions of the brain, the disruption in inhibitory and excitatory 
balance resulting from PV interneuron dysfunction has broad functional implications. We propose 
that the action of NIC administration in normalizing vHipp and VTA neuronal activity in MAM 
animals observed in our studies may occur via potentiation of inhibitory activity in the vHipp 
(Figure 12). Both 7 and 42 nAChRs are expressed on GABAergic interneurons of the vHipp, 
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including PV interneurons (Alkondon and Albuquerque 2002). These inhibitory cells potently 
modulate pyramidal cell spiking, and activation and desensitization kinetics of the nAChRs 
expressed on these neurons can thus have major effects in modulating inhibition and disinhibition 
of pyramidal cells (Ferguson and Gao 2018). Interestingly, high plasma NIC levels observed in 
SCZ smokers (McKee et al. 2009) may be particularly effective in activating low-affinity 7 
nAChRs in addition to higher affinity receptors. Additional evidence suggests that, in addition to 
desensitization following activation, these receptors desensitize with sustained exposure to 
subthreshold agonist concentrations (Olale et al. 1997). This could suggest that constant low levels 
of NIC may fail to produce any activation of 7 nAChRs, while NIC levels associated with 
distinctly heavy smoking patterns may produce unique effects in activating these receptors.  
 Prior studies have demonstrated that 7 nAChR stimulation in vHipp is sufficient to 
normalize elevated DA population activity (Neves and Grace 2018), and our experiments suggest 
that activation of multiple nAChR subtypes by systemic NIC administration produces 
normalization of both elevated DA population activity and vHipp hyperactivity in MAM animals. 
Importantly, these effects were not observed in control animals, suggesting a mechanism unique 
to MAM pathophysiology. Reductions in 7 nAChR expression in this region demonstrated by 
our lab (Appendix 1), as well as highly documented PV interneuron dysfunction in MAM animals 
(Gill and Grace 2014), are two potential candidate mechanisms by which nicotinic activation may 
uniquely potentiate vHipp inhibitory balance in MAM animals. Our autoradiography data cannot 
discern whether this reduction in 7 nAChR expression is specific to PV interneurons. However, 
direct comparisons of 7 receptor concentrations in control animals showed minimal expression 
in CA1 pyramidal cells, with high expression in interneurons (Frazier et al. 1998), making this a 
likely possibility. Additionally, while our electrophysiological experiments focused on activity in  
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Figure 12: Schematic of proposed mechanism of NIC in vHipp 
(A) vHipp-NAcc-VP circuit disruption leading to elevated VTA DA population activity. Inhibitory 
dysfunction in vHipp (decreased PV expression/reduced activation of inhibitory interneurons due to 
reduced expression of 7 and 42 nAChRs) contributes to elevated excitatory output to NAcc. Inhibitory 
projections from NAcc which typically modulate VP inhibition and disinhibition of VTA are thus also 
increased. This produces a constant state of disinhibition to VTA (dashed line) and, in turn, abnormally 
high tonic DA activity. (B) Proposed action of NIC in vHipp (inset). NIC activation of 7 and 42 
nAChRs on inhibitory interneurons, including the reduced population of PV interneurons, potentiates 
GABA input to pyramidal cells, normalizing activity. 7 nAChRs expressed on presynaptic terminals of 
glutamatergic inputs to pyramidal cells desensitize quickly, reducing their potentiation of transmitter 
release. 42 and 43 nAChRs on inhibitory interneurons and on presynaptic terminals of glutamatergic 
inputs exciting them desensitize more slowly, favoring sustained potentiation of inhibitory input to 
pyramidal cells. Pyramidal cells, PC; parvalbumin-positive interneuron, PVI. 
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vHipp and VTA, it is important to note that the effects of systemic NIC administration are relevant 
throughout the brain. Modulation of vHipp excitation has important implications for 
excitation/inhibition balance between hippocampus and PFC, as well as other hippocampal 
projection regions. Nicotinic stimulation undoubtedly has direct neuronal effects in PFC as well, 
where similar decreases in PV interneuron function are observed in both humans and MAM 
animals (Beasley and Reynolds 1997; Gastambide et al. 2012), though detailed conjectures 
regarding effects in this region are beyond the scope of our experimental results. However, 
modulation of excitation/inhibition balance within and between these regions could provide a 
general mechanism by which NIC administration improves sensory gating and cognitive deficits 
in the MAM model, as described in Chapter 3. Prior evidence has suggested that 42 nAChR 
agonism is sufficient to potentiate GABAergic activity and reverse impairments in a multisensory 
integration task in rodents with experimentally inhibited PV interneurons in orbitofrontal cortex 
(Cloke et al. 2016), which suggests the potential of a similar mechanism in the behavioral effects 
of NIC we observed in MAM animals.  
While some clinical evidence suggests that acute effects of NIC on cognitive function and 
sensory gating impairments in SCZ smokers may reflect a reversal of withdrawal-induced deficits 
rather than a positive effect, our findings did not demonstrate such an impact on baseline function 
after brief NIC withdrawal. After chronic NIC treatment, we demonstrated that MAM and CTL 
animals were comparable in both behavioral and electrophysiological measures at a 24-hr 
abstinence baseline. These findings do not rule out the possibility of such an effect, as our 
experiments utilized a daily injection protocol that may not completely capture the patterns of NIC 
exposure and withdrawal symptoms experienced by human smokers. However, they do suggest 
that repeated exposure to moderate NIC doses does not necessarily result in compensatory 
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neurophysiological alterations that negatively impact function in the acute absence of NIC. 
Interestingly, some evidence suggests that nAChR upregulation after chronic NIC exposure may 
be less robust in brains of SCZ smokers than of controls. An imaging study using radiolabeled 2 
nAChR agonist drug found lower receptor availability in SCZ smokers than in control smokers in 
frontal cortex, parietal cortex, and thalamus (D’Souza et al. 2012). Additionally, studies of 
postmortem tissue found significantly lower upregulation of 42 binding in SCZ smokers than 
control smokers in hippocampus, cortex, and caudate (Breese et al. 2000). Our findings, when 
placed in the scope of existing literature, suggest effects of NIC in MAM pathophysiology that are 
distinct from those observed in controls, and likely illustrate the potential of NIC potentiation of 
inhibitory balance in MAM animals as a means of normalizing SCZ-related behavioral and 
neurophysiological perturbations. Further studies can better elucidate the detailed 
neurophysiological basis of these effects as well as their direct connections to related behaviors. 
5.4 LIMITATIONS AND CONSIDERATIONS 
Several key considerations must be made in evaluating the data presented here. First and 
foremost, experiments utilizing the MAM rodent model of SCZ, or any animal model of SCZ, will 
always be limited by the fact that SCZ is a distinctly human disease. There is no single known 
etiology of SCZ, precluding the precise replication of the disease state in an animal model, and it 
is characterized largely by its symptoms. Though we cannot experimentally study psychosis in 
animals, we are able to model neurophysiological correlates of psychosis and other disease-
relevant system features. Importantly, the MAM rodent model has core features of face validity in 
modeling SCZ, including measurable positive-like symptoms reflecting abnormal DA function 
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such as sensory gating dysfunction, as well as cognitive impairments and limited negative 
symptom analogs (Modinos et al. 2015). Additionally, this model has a relatively high degree of 
predictive validity, as antipsychotic drugs effectively ameliorate analogs of psychosis 
(Sonnenschein and Grace 2020), and induction of the model through neurodevelopmental 
disruption informs some understanding of disease etiology. Our studies of NIC effects in the MAM 
model, however, are limited in modeling human NIC use in several key respects. Firstly, our self-
administration studies described in Chapter 2, while effective in assessing reinforcing effects of 
NIC alone, cannot capture the full spectrum of experiential and psychosocial factors that may 
contribute to continued smoking in human SCZ patients. Additionally, if smoking in SCZ patients 
is reinforced by the effects of NIC intake on “feeling better” rather than the rewarding effects of 
NIC, it would not be possible to assess this type of motivation in an animal model, as we cannot 
necessarily discern if “feeling better” (i.e. ameliorating some negative/cognitive symptoms, even 
if captured in the model) would drive self-administration behavior. Furthermore, the experiments 
of Chapters 3 & 4 utilized a drug administration protocol of daily, experimenter-administered 
subcutaneous injection of NIC at a single moderate dose in order to control for the specific timing 
and quantity of NIC each animal received. Indeed, NIC exposure in this injection protocol is not 
equivalent to the consistent, repeated dosing throughout the day experienced by heavy smokers, 
and 24-hour abstinence from these injections undoubtedly differs from an overnight withdrawal 
baseline typically measured in studies of human smokers. While the doses utilized in our 
experiments were sufficient to normalize behavioral and electrophysiological dysfunction in 
MAM animals, further exploration of dose-response relationships for NIC in these measures are 
warranted.  
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Another potential factor for consideration is that most SCZ smokers studied in clinical 
experiments are taking APDs at the time of study, which was not the case for animals used in our 
experiments. Our findings do provide useful insight about the effects of NIC in unmedicated 
smokers with SCZ as well as potential effects on cognitive and negative symptoms, which are not 
effectively managed with APDs (Goff et al. 2011). However, it is possible that APD treatment 
status could produce alterations that modulate NIC reinforcement, affecting self-administration, or 
have system-wide modulatory implications for effects on cognitive deficits and neurophysiological 
perturbations in the MAM model. Similarly, levels of monoamine oxidase-A (MAO-A) and MAO-
B activity in the brains of smokers are inhibited by approximately 30-40% due to an unidentified, 
non-NIC constituent of cigarettes (Lewis et al. 2007). Comparable pharmacological MAO 
inhibition has been shown to increase NIC self-administration in control rats (Smith et al. 2015) 
and MAM rats (Weeks, unpublished), though further potential effects on cognitive and 
neurophysiological function have not been assessed. Future experiments could explore what, if 
any, effect APD treatment and MAO inhibition may have on the behavioral and 
neurophysiological effects of NIC observed in our studies.  
An additional important technical limitation to consider in evaluating our experimental 
findings is the dissociation of our behavioral and electrophysiological experiments. In separate 
experiments, we determined that acute and chronic NIC can normalize both behavioral and 
neurophysiological perturbations observed in the MAM model. Because of this separation, our 
utilization of extracellular recording in anesthetized animals precludes any conclusions directly 
connecting the normalization of elevated vHipp and VTA activity with normalization of cognitive 
and sensory gating impairments. Ultimately, because systemic NIC administration was utilized, 
we also cannot draw any certain conclusions regarding the precise mechanism by which NIC 
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administration normalized vHipp activity due to distribution of nAChRs throughout the brain. 
Thus, while the observed effects on activity in vHipp likely have implications for the balance of 
activity throughout the brain, we cannot determine precisely how normalization of vHipp activity 
and resulting impact on afferents from this region may translate to behavioral outputs. Direct 
stimulation of nAChRs in other regions, such as PFC, are also likely to play a role in the effects of 
NIC on NOR and PPI. Regionally specific pharmacological manipulation and electrophysiological 
recording in awake, behaving animals would be a critical step in ascertaining possible connections 
between our behavioral and neurophysiological observations.   
5.5 IMPLICATIONS FOR PHARMACOTHERAPIES AND SMOKING CESSATION IN 
SCHIZOPHRENIA 
Our studies sought to explore the neurophysiological and behavioral effects of smoking-
relevant doses of NIC in a well-validated animal model of SCZ in order to assess how these effects 
may influence heavy smoking in SCZ patients. An understanding of the impact of NIC in daily 
functioning of SCZ smokers is critical to the development of successful cessation strategies as well 
as potential pharmacotherapies for negative and cognitive symptoms of the disease. Our findings 
suggested that acute systemic administration of NIC can normalize impairments in PPI and NOR, 
as well as neuronal hyperactivity in vHipp and VTA, observed in MAM animals. Importantly, we 
also found that this normalization appears to persist in animals chronically treated with NIC, even 
when measured at a 24-hr abstinence period, a finding which may have important implications for 
smoking cessation strategies as well as potential NIC reduction policy. Smokers with SCZ are 
consistently less successful in smoking cessation attempts despite considerable motivation to quit 
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(Cather et al. 2017), and this difference is often attributed to particularly severe withdrawal 
symptoms in this population. In a study of brief abstinence in smokers with SCZ and 
nonpsychiatric controls, SCZ subjects reported more severe cigarette craving and withdrawal 
symptoms throughout the 72-hr abstinence period. Moreover, this group reported greater NIC 
preference after abstinence and lapsed back to smoking significantly sooner than controls (Tidey 
et al. 2014). Some evidence also suggests that withdrawal may exacerbate cognitive impairments 
in SCZ smokers. In a study of VSWM task performance, 1-week abstinence improved performance 
in control smokers, but further impaired smokers with SCZ (George et al. 2002). However, other 
studies have demonstrated a lack of effect of both brief and prolonged abstinence on cognitive 
performance in SCZ smokers (Boggs et al. 2018). Our findings of similar performance in briefly 
abstinence CTL and MAM animals suggest that exacerbation of SCZ-related dysfunction, at least 
in the short term, may not be a primary component of particularly severe withdrawal symptoms in 
this population. This parallels findings that SCZ smokers are comparable to controls in effects of 
smoking abstinence and resumption on attentional performance, but report significantly higher 
withdrawal symptoms than controls (Hahn et al. 2013). Implications for negative symptom 
severity also could not be assessed in our experiments, which remains a possible component of 
persistent smoking in SCZ.  
Understanding the effects of chronic NIC use and abstinence on functioning in SCZ 
smokers is particularly critical to the development of a reduced-NIC product standard aimed at 
reducing smoking, as disparate effects of NIC reduction could drive compensatory smoking in this 
population. However, trials of very-low-NIC-content (VLNC) cigarettes in smokers with SCZ 
have yielded promising results. A six-week trial of VLNC cigarettes in control and SCZ smokers 
demonstrated that, relative to usual brand smokers, those on VLNC performed more poorly on 
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measures of attention, working memory, inhibitory control, and processing speed regardless of 
psychiatric status. However, this difference was not observed in SCZ smokers given NIC 
replacement therapy (NRT) while smoking VLNC cigarettes, suggesting that NRT may effectively 
preserve cognitive functioning (AhnAllen et al. 2015). Another trial of VLNC versus normal NIC 
content cigarettes in SCZ smokers demonstrated that those in the VLNC condition smoked fewer 
cigarettes per day, had lower breath carbon monoxide levels, and comparable psychiatric 
symptoms to those in the normal NIC condition. Importantly, however, total NIC exposure did not 
differ between conditions, which suggests that smokers in the VLNC condition likely 
supplemented with alternative sources of NIC (Tidey et al. 2019). These findings suggest that SCZ 
smokers would likely respond to reduced NIC product standards in a similar manner to 
nonpsychiatric controls, but that alternative sources of NIC, such as NRT or e-cigarettes, may be 
an important tool in maintaining abstinence. Additionally, while it cannot be addressed in animal 
studies, it is key to acknowledge the unique psychosocial barriers to cessation faced by this 
population, such as a lack of provider support. In addition to the use of NRT or alternative NIC 
sources in smoking cessation, evidence suggests that integration of provider and peer support is 
particularly necessary in achieving cessation among SCZ smokers (Cocks et al. 2019). 
The effects of NIC on measures of sensory gating and cognitive impairment observed in 
our studies also offer important insight to the development of potential pharmacotherapies for 
cognitive symptoms in SCZ. Despite the wealth of research largely focused on the 7 nAChR as 
a therapeutic target, there has been little success in drug development. The receptor’s unique traits 
make it a challenging target for agonist drugs, as activation of the receptor produces rapid and 
profound desensitization, limiting the efficacy of sustained drug exposure. Initial clinical studies 
of 7 agonists and partial agonists have shown some significant improvements in cognitive 
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performance and sensory gating measures after acute administration. Efforts to develop an 
extended-release 7 nAChR agonist have found little efficacy in increasing cognitive performance 
in smokers or nonsmokers (Kem et al. 2018). While no 7 nAChR drug has succeeded in larger 
Phase III trials, development of potential 7 ligands, particularly positive allosteric modulators 
(PAMs) of the receptor, continues as a challenging avenue in improving cognitive symptoms of 
SCZ (Tregellas and Wylie 2019; Freedman 2014). Our findings highlight the potential utility of 
cognitive symptom pharmacotherapies targeting multiple nAChR subtypes rather than a focus on 
the 7 nAChR alone. The effectiveness of both acute and chronic NIC in normalizing behavioral 
and neurophysiological disruptions in MAM animals suggest a benefit of general nicotinic 
stimulation in the SCZ pathophysiology modeled by gestational MAM. This approach may have 
relevance to the development of more effective pharmacotherapies both for cognitive dysfunction 
and smoking cessation in SCZ patients. As described previously, NRT is generally promising as a 
smoking cessation aid in SCZ smokers and does not present adverse neuropsychiatric side effects 
(Shawen and Drayton 2018). Drugs aimed at aiding cessation such as varenicline, a full agonist of 
7 nAChRs and partial agonist of 42 nAChRs, can have limited efficacy in patients with higher 
negative symptom severity (Dutra et al. 2012). However, double-blind studies do suggest that 
varenicline is more effective than placebo in significantly decreasing NIC intake and smoking 
urges among individuals with SCZ, though it does not differ from placebo in effects on psychiatric 
symptom severity (Smith et al. 2016). Stimulation of multiple nAChR subtypes at a level similar 
to NIC administration may thus be important for optimal efficacy in improving SCZ negative and 
cognitive symptomology and minimizing adverse effects of NIC withdrawal in this population.  
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5.6 FINAL CONCLUSIONS 
In summation, the findings of our studies suggest that SCZ pathophysiology modeled by 
GD17 MAM administration does not produce increased NIC reinforcement relative to controls, 
suggesting that greater NIC reward alone is likely not a driver of increased smoking in SCZ. Our 
further studies demonstrated that acute and chronic systemic administration of NIC can normalize 
SCZ-relevant sensory gating and cognitive impairments observed in MAM animals. Additionally, 
acute and chronic NIC administration normalized elevations in VTA DA population activity, as 
well as the elevated vHipp neuronal activity thought to drive abnormal DA activity. Together, 
these findings suggest that nicotinic stimulation throughout the brain can have positive effects on 
behavioral dysfunction in the MAM model, as well as the imbalance in excitatory and inhibitory 
neuronal activity thought to underlie such dysfunction. These results provide evidence that effects 
of NIC on cognitive and negative symptoms of SCZ could be a potential driver of continued heavy 
smoking in SCZ. Importantly, these studies suggest the utility of future studies better clarifying 
the connection between NIC use and SCZ symptomology and elucidate pathways for future 
exploration of this relationship. We hope that such understanding can inform development of more 
efficacious pharmacotherapies for cognitive dysfunction in SCZ, as well as more targeted 
strategies for smoking cessation in this population.  
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APPENDIX A  AUTORADIOGRAPHIC ANALYSIS OF 7 NACHR EXPRESSION 
 
Figure 13: Reduced expression of vHipp alpha7 nAChRs in male MAM rats 
Quantitative receptor autoradiography conducted using [125I]--bungarotoxin in slices from brains of MAM 
and CTL rats demonstrated a sex-specific reduction in 7 receptor expression in vHipp of male MAM 
animals. Two-way ANOVA of [125I]--bungarotoxin binding demonstrated a significant Group x Sex 
interaction (p < 0.05). Post-hoc t-tests demonstrated that binding of [I125]-bungarotoxin in vHipp was 
significantly lower in male MAM animals than both male CTL animals and female MAM animals. *p < 
0.05. 
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